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Neural stem cells (NSCs) give rise to all the major cell types in the brain, including neurons, 
oligodendrocytes, and astrocytes. However, the intracellular signaling pathways that govern brain NSC 
proliferation and differentiation have been incompletely characterized to date. Since several 
neurodevelopmental brain disorders (i.e., Costello syndrome, Noonan syndrome) are caused by germline 
mutations in the RAS genes, Ras small GTPases are likely critical regulators of brain NSC function. In the 
mammalian brain, Ras exists as three distinct molecules (H-Ras, K-Ras, and N-Ras), each with different 
subcellular localizations, downstream signaling effectors, and biological effects. Leveraging a novel series 
of conditional Ras molecule-expressing genetically-engineered mouse strains, we demonstrate that K-
Ras, but not H-Ras or N-Ras, hyperactivation increases brain NSC growth in a Raf-dependent, but Mek-
independent, manner. Moreover, we show that K-Ras regulation of brain NSC proliferation requires Raf 
binding and suppression of retinoblastoma (Rb) function. Collectively, these observations establish 
tissue-specific differences in Ras molecule regulation of brain cell growth that operate through a non-
canonical mechanism. 
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CHAPTER 1  
INTRODUCTION 
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DEVELOPMENT OF THE MAMMALIAN BRAIN 
 The gross cellular composition of the mammalian brain arises through sequential specification of 
three main types of cells.  Neurons, the cells responsible for conducting neural signals in the mature 
brain, appear first, followed by the development of two types of neuronal support cells, astrocytes and 
oligodendrocytes.  The temporal differentiation of individual cell types has been well characterized in rat 
models of brain development, which demonstrate that neurons first appear around embryonic day 12 
(E12) and continue to develop through E18  (Figure 1.1) [1]. Following neuronal specification, astrocytes 
first appear at E18, followed closely by oligodendrocytes at postnatal day 1 (PN1).  Both cell types 
continue to develop through early postnatal time points.  While similar, the temporal sequences of rat and 
mouse embryonic brain development do not perfectly correlate.  As indicated in Figure 1.1, mice begin to 
develop neurons at E10.5, astrocytes at E15.5, and oligodendrocytes at PN1 [2].  For simplicity, mouse 
development time points are used throughout this thesis document, unless otherwise noted.  The timeline 
of cell specification is ultimately unsurprising; a neuronal network must be in place before the cells 
responsible for insulating (oligodendrocytes) and maintaining neurons (astrocytes) can establish 
themselves in appropriate proximity to the network.  The temporal segregation of cell type-specific 
development requires a carefully orchestrated integration of temporal cues and cell-extrinsic/intrinsic 
signals to drive brain multipotent progenitors, neural stem cells (NSCs), towards the correct cell fates. 
 
The Keystone of Brain Development: Neural Stem Cells 
 NSCs give rise to all major cell types in the brain, including neurons, astrocytes, and 
oligodendrocytes, thereby underscoring the importance of these progenitor cells for mammalian brain 
development.  In order to specify all three subtypes, these progenitor cells must arise early in embryonic 
development prior to neuronal fate specification.  Multi-potent progenitor cells have been isolated from the 
rat spinal cord at rat E10.5, providing evidence for NSC populations that arise from the primitive neural 
tube before localizing throughout the developing central nervous system (CNS) [3, 4].   
In order to characterize NSCs, a series of in vitro studies sought to isolate and define progenitor 
cell populations at specific time points throughout the course of embryonic brain development.  
Multipotent blast cells were first isolated during mid-embryogenesis in the developing rat brain (rat E13.5, 
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E14.5) using in vitro clonal culture techniques [5].  While the majority of the resulting clones gave rise to 
either neurons or glia alone, a subset (22%) of these clones contained both neuronal and non-neuronal 
cell types.  These findings represented the first isolation of a rudimentary progenitor cell, and 
demonstrated that neural progenitor cells have the capacity to generate both neuronal and glial cell 
lineages.  Subsequently, progenitor cell populations were isolated from the E14 mouse striatum and could 
be cultured in the presence of epidermal growth factor (EGF).  In culture, these cells spontaneously form 
spheres of proliferating cells (the field would later term these “neurospheres”) that express the 
neurofilament protein Nestin, a marker previously found exclusively in progenitor cells from the 
neuroepithelium.  Moreover, EGF-responsive neurospheres possess many of the hallmarks of progenitor 
cell populations in that these cells are capable of self-renewal over multiple passages and can undergo 
multi-lineage differentiation into neurons, astrocytes, and oligodendrocytes in culture [6, 7].  Later work 
also isolated NSCs earlier in embryonic development using the closely related fibroblast growth factor 
(FGF) [8].  As with EGF-responsive NSCs, FGF-responsive cells also demonstrated a capacity to adopt 
all three terminally differentiated cell fates [9].  Taken together, these studies not only define a temporal 
window during which NSCs appear, but also establish a foundation for in vitro culture studies of these 
progenitors for careful evaluation of their cell-autonomous properties. 
The maintenance of NSCs during development requires several extracellular signals, including 
Notch and leukemia inhibitory factor (LIF) [10-12].  In NSCs, the Notch ligand activates several 
downstream effector components, including Janus kinase (JAK) and signal transducer and activator of 
transcription (STAT) transcription factors to promote NSC survival [11].  A role for LIF in maintaining NSC 
identity is apparent upon overexpression in the adult brain, which reduces neurogenesis and promotes 
NSC self-renewal [10].  Given its role in pro-glial signaling later in brain development (discussed below), it 
is possible that LIF primarily functions in inhibiting neuronal cell fate decisions while driving NSC self-
renewal early in development and promoting gliogenesis later in development.  
The differentiation of NSCs towards the three cell lineages depends partially on temporal 
regulatory restrictions.  Using clonal differentiation assays, Qian, et al., elegantly demonstrated that 
Nestin+ NSCs maintained in vitro first develop into neurons, as revealed by expression of the neuronal 
marker Tuj1 around the in vitro equivalent of E11 [13].  Glial differentiation occurred shortly thereafter, 
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evidenced by glial fibrillary acidic protein (GFAP) expression at E16 (astrocytes) and O4 expression 
around P3-P4 (oligodendrocytes).  Early studies suggested that NSC lineage specification depends solely 
on a small subset of growth regulatory proteins: neurons by platelet-derived growth factor (PDGF), 
astrocytes by ciliary neurotrophic factor (CNTF), and oligodendrocytes by thyroid hormone T3 [14].  While 
fundamentally consistent, later studies would demonstrate that NSC fate specification is dependent on a 
more expansive list of coordinated signaling molecules to specify each cell fate.  These signals merit 
further discussion in the context of each cell type. 
Since most studies focused on defining NSC populations in the embryonic brain, it was thought 
that few, if any, progenitor cells persisted in the postnatal brain.  This led to the false conclusion that an 
exhausted NSC pool limited the capacity of the brain to regenerate after birth and into adulthood.  
Subsequent studies have identified concentrated populations of NSCs within the neurogenic regions of 
the adult brain, including the hippocampal subventricular zone (SVZ), the third ventricular zone, and the 
fourth ventricular zone [15-17].  Perhaps the most well-characterized of these regions, the hippocampal 
SVZ, contains a hierarchy of precursor cells that include glial-like progenitor cells (Type B cells), which 
generate Type C transit-amplifying cells.  These type C cells ultimately give rise to Type A neuronal 
precursor cells [16, 18].  Although Type B cells have the capacity to form multi-potent neurospheres in 
vitro, in vivo programming directs these cells to replace only neurons within the olfactory bulb [18, 19].  
Progenitors within the third ventricle can also give rise to neurons, but not other cell types, suggesting 
that postnatal NSCs are directed most often towards neuron cell fates [15].  The overall plasticity of these 
progenitor cell populations may also be regionally-restricted, such that progenitors in different regions 
only give rise to certain neuronal subtypes [20].  Over the course of aging in the adult brain, the 
neurogenerative capacity of these cells is reduced.  Within the SVZ, NSCs undergo increased 
asymmetric divisions that favor astrocyte over neuron formation and deplete the existing NSC pool [21].  
Taken together, these studies demonstrate that a large population of embryonic NSCs readily exhibits a 
capacity for high proliferation and multi-lineage differentiation.  This capacity allows for a high number of 
diverse cell types to be generated in a relatively brief period of time during brain development.  In 
contrast, the adult brain contains a much smaller pool of NSCs that primarily function in maintaining 
existing neurons within the brain.  
	   5 
Building a Neuronal Network 
 To initiate brain development, NSCs first differentiate into the neuronal lineage.  This cell fate is 
specified by a number of cell-intrinsic and cell-extrinsic factors which promote neurogenesis and 
simultaneously suppressing gliogenesis (Figure 1.2).  Several basic helix-loop-helix (bHLH) transcription 
factors, including Neurogenin 1 and 2 (Ngn1, Ngn2), mammalian achaete-scute homologue (Mash1), and 
Math3, function to drive progenitor cells toward neuronal lineages [22, 23].  Genetic knockout studies of 
the individual Mash1 and Math3 genes has a minimal effect on neurogenesis in vivo; however, double 
knockout mice exhibit a significant loss of hindbrain neurons [23].  Progenitor cells in these mice that are 
normally committed to become neurons instead adopt a glial cell fate.  This finding reveals a significant 
collaboration between Mash1 and Math3 to simultaneously promote neurogenesis and suppress 
gliogenesis.  The same is also true for Ngn1, which promotes neurogenesis as a transcriptional activator.  
Ngn1 simultaneously inhibits astrogliogenesis by sequestering the CBP-Smad 1 signaling compounds 
while inhibiting STAT transcription factor function, which promotes astrocyte differentiation later in brain 
development (see below).  Introduction of pro-neuronal bHLH genes at postnatal time points no longer 
promotes neurogenesis or blocks gliogenesis, demonstrating that their pro-neuronal signals are 
temporally restricted to embryonic tissues [22].  
 Extrinsically, ligands of the bone morphogenic protein (BMP) family promote NSC differentiation 
into neurons during the neurogenic period of brain development.  Early studies demonstrated that the 
addition of the BMP4 ligand to explant cultures promotes expression of the Tuj1 neuronal marker in cells 
within the ventricular zone [24].  Moreover, a dominant negative BMP receptor (interfering with normal 
BMP-receptor signaling) blocked neuronal migration from this ventricular zone.  This demonstrates that 
BMP is required for the regulation of neuronal cell fates in ventricular zone progenitor cells.  
Characterization of BMP2 in cultured rat cortical progenitor cells identified a temporally-restricted role for 
these ligands in promoting neuronal differentiation [25].  At the beginning of the neurogenic period (rat 
E13), addition of BMP2 inhibits proliferation and suppresses both neurogenesis and gliogenesis.  
However, the addition of moderate doses of BMP2 later in the neurogenic period (rat E16) drives 
neuronal differentiation, identifying a time-dependent role for BMP-mediated neurogenesis in the 
developing brain.  Mechanistically, BMP ligands bind TGF-β membrane receptors to activate the Smad 
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family of transcription factors and drive cell fate decisions.  To date, the exact mechanism of BMP-
mediated promotion of neurogenesis is unclear, although in the adult, neurogenesis relies on the Smad4 
protein [26].  Taken together, these data demonstrate a time-dependent, pro-neuronal role for BMP 
ligands, a fact that has additional relevance during the gliogenic period, as discussed below.  
The mitogen/extracellular signaling-regulated kinase (MEK) and extracellular signaling-regulated 
kinase (ERK) effector proteins may also mediate extracellular signals that promote progenitor cell 
neurogenesis [27, 28].  In cultured cortical progenitor cells, inhibition of either Mek or its downstream 
effector protein, Erk5, inhibits neurogenesis, indicating a direct requirement for both effector proteins in 
mediating pro-neurogenic signals [28, 29].  The downstream C/EBP family of transcription factors is also 
required for normal neurogenesis, defining a Mek- and C/EBP-mediated pro-neurogenic regulatory 
pathway.  Mechanistically, Mek phosphorylates (activates) C/EBP.  In fact, C/EBP alone is sufficient to 
promote neurogenesis, as demonstrated by expression of a constitutively active member of the C/EBP 
family (C/EBPβ) in cortical progenitor cells [27].  C/EBP may also function in repressing pro-glial fate 
decisions in these same progenitor cells.  When directed towards a glial cell fate using the CNTF 
cytokine, cortical progenitors differentiate into more astrocytes when C/EBP activity is inhibited [28].  
 The combination of these cell-intrinsic and cell-extrinsic factors is critical to direct NSCs towards 
neurogenic cell fates during a defined period of brain development.  Subsequent brain development 
requires a switch to inhibit neurogenesis and instead direct NSCs towards glial cell fates to support the 
newly formed neuronal network. 
 
Supporting the Neuronal Network: Astrocytes 
 In the adult brain, astrocytes function in neuronal maintenance by providing structural support, 
modulating blood flow, facilitating nutrient delivery, and absorbing waste and excess neurotransmitters 
[30].  To facilitate the formation of these astrocytes, formerly pro-neurogenic signals are inhibited and pro-
astroglial signals are activated in NSCs around E15.5 (Figure 1.3).  One regulatory mechanism 
underlying this switch relies on temporally-restricted methylation at two CpG dinucleotide sites upstream 
of the astrocyte-specific genes, glial fibrillary acidic protein (GFAP) and S100β [31, 32].  Within the 
promoter of the astrocytic Gfap gene, CpG methylation obstructs the binding of the STAT3 transcription 
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factor and prevents Gfap transcription [32].  Alternatively, CpG methylation within the promoter for a 
second astrocyte gene, S100β, facilitates binding of the methyl DNA binding protein (MeCP2), which 
enables inhibitory histone deacetylateses and other co-repressor proteins to bind and inhibit S100β  
expression [31].  During the neurogenic period at E11.5, methylation at both sites inhibits expression of 
either gene and can not be initiated even upon overexpression of the STAT3 transcription factor [32].  
These promoters are only demethylated at the start of the gliogenic period (E14.5), thereby allowing 
transcription factor binding and subsequent Gfap and S100β expression [31, 32].   
 In addition to these cell-intrinsic regulatory mechanisms, extracellular pro-gliogenic signals 
increase at the start of the gliogenic period [33].  Many of these signals operate through growth factor 
binding to the gp130 family of membrane receptors.  The importance of these receptors for gliogenesis  
apparent in mice deficient for gp130 receptors, which have increased neuronal cell death and reduced 
formation of GFAP+ astrocytes in the brain [34].  This demonstrates a dual role for the gp130 receptors 
(and their associated growth factor ligands) in both promoting neuron survival and driving astrocyte 
differentiation.  The gp130 receptors signal by homo- and hetero-dimerization of individual receptor family 
members, which transduces signals from a variety of cytokines, including the pro-astrocytic factors 
cardiotrophin-1 (CT-1), CNTF, and LIF [35, 36].  The pro-astrocytic growth factor CT-1 is secreted by 
neighboring neurons to foster the development of astrocytes within proximity of newly developed axons 
and synapses.  Loss of CT-1 expression in the developing brain reduces astrocyte formation, 
demonstrating a partial requirement for this cytokine in driving astrocyte differentiation [37].  The fact that 
only some astrocytes don’t develop in CT-1-/- brains indicates that other growth factors must be involved 
in facilitating astrocyte differentiation.  In vitro, the CNTF growth factor induces cortical progenitor cells to 
become astrocytes, a process which continues even after CNTF is removed from the culture media.  The 
persistence of CNTF-mediated pro-glial signals demonstrates that CNTF irreversibly specifies astrocyte 
cell fate decisions and suggests that this cytokine is involved in the permanent switch from pro-
neurogenic to pro-astrocytic cell fate decisions [38].  Lastly, the loss of the receptor for the pro-glial 
cytokine LIF causes decreased astrocyte differentiation in vivo and in vitro [39].  As discussed below, LIF 
signaling specifies astrocyte differentiation in collaboration with BMP signaling, underscoring an important 
role for LIF in pro-astrocytic cell fate decisions.  Together, these results demonstrate that coordinated 
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signaling from a diverse set of pro-astrocytic cytokines is required for development of the full complement 
of astrocytes in the mature brain.  Despite the diversity of cytokines operating during the pro-gliogenic 
brain development phase, these cytokines collectively signal to the gp130 downstream JAK effector 
protein to activate the glial-promoting STAT3 transcription factor [37, 38, 40].  
 Operating independently of gp130 and its associated growth factor ligands, Notch has also been 
identified as an important driver of astrocyte differentiation.  This aspect of Notch signaling was originally 
demonstrated in neural crest stem cells of the peripheral nervous system.  Upon activation of Notch, 
neurogenesis of these stem cells was suppressed while astroglial cell fates were increased [41].  Shortly 
thereafter, Notch signaling was also identified as a pro-astrocytic signal for hippocampal stem cells in the 
developing CNS [42].  Since Notch signaling requires cell-cell contact, Notch-mediated astrogliogenesis 
may be triggered by neighboring neuroblasts, which direct these stem cells to adopt an astroglial cell fate 
[41].  Similar to some gp130 ligands (CNTF), Notch irreversibly commits progenitor cells to the astrocyte 
lineage, suggesting a role for Notch is specifying the pro-neuronal to pro-glial signaling switch during 
brain development [42].  
In addition to its early role in pro-neuronal signaling, BMP also drives progenitor cells towards the 
astrocyte fate during the gliogenic phase of brain development [43].  During this period, BMP now 
suppresses neurogenesis and restricts oligodendrocyte fate decisions [25, 43].  This is partially mediated 
by BMP2-dependent increases in expression of the transcription factors Id2, Id3, and Hes-5 which inhibit 
the expression of the pro-neuronal factors Mash1 and Ngn1 [44, 45].  Moreover, BMP2 expression 
inhibits the expression of the progenitor gene Nestin and the Map2 neuronal gene.  BMP2 also increases 
expression of the S100β astrocyte gene, thereby indicating that BMP2 expression drives progenitor cell 
development towards astrocyte rather than neuron cell fates [44].  This presents an important question: 
how can the same pro-neuronal signaling molecule (BMP) also promote astrocyte differentiation later in 
development?  The mechanism underlying this switch to pro-astroglial fate choice relies on synergistic 
signaling with the pro-astrocytic LIF cytokine.  At this stage, activation of either BMP2 or LIF alone drives 
only limited astrocyte fate specification, underscoring the importance of coordinated signaling from both 
molecules for normal astrocyte development [40].  Operating downstream of both LIF and BMP, the 
transcriptional coactivator p300 acts as a bridge between these two pathways by binding STAT3 (the LIF-
	   9 
mediated transcription factor) at its N-terminus and Smad1 (the BMP2-mediated transcription factor) at its 
C-terminus [40].  As a result, this bridge protein coordinates the input from both cytokines and allows 
BMP to signal in a pro-glial manner. 
  
Supporting the Neuronal Network: Oligodendrocytes 
 Oligodendrocytes are the third and final cell type to differentiate from NSCs during brain 
development.  Upon differentiation, these cells function in forming an insulating, lipid-rich myelin sheath 
around neuronal axons to enhance electrical conduction of the nerves [30].  Oligodendrocytes derive 
primarily from glial-restricted progenitor cells (GRPCs), which give rise to astrocytes and 
oligodendrocytes, but not neurons, in the brain and spinal cord [46, 47].  However, in the spinal cord 
alone, oligodendrocytes and motor neurons can also derive from a shared progenitor cell population [48, 
49].  In the brain, the primary pool of oligodendrocyte precursors arises from the ventral forebrain, 
although additional sources have been identified within the ganglionic eminences and in the postnatal 
neocortex [50].  Genetic ablation of any single oligodendrocyte precursor population does not disrupt 
normal oligodendrocyte development, indicating that these pools can compensate for shortages of any of 
the original progenitor pools.  
Regionally-restricted differentiation signals are thought to direct GRPCs to adopt either astrocyte 
or oligodendrocyte cell fates during CNS development.  In the chick spinal cord, oligodendrocyte 
differentiation is induced by Sonic hedgehog (Shh) signaling and antagonized by BMP signaling [51, 52].   
The expression of both ligands is regionally restricted—BMP from the dorsal portion of the spinal cord, 
Shh from the ventral floor plate—allowing the formation of a signaling gradient that provides positional 
cues for glial cell differentiation.  In the brain, Shh is expressed along the ventral midline at the 
telecephalon/diencephalon border in an area containing oligodendrocyte precursor cells [53].  This Shh 
expression overlaps with the expression of two pro-oligodendroglial bHLH transcription factor genes, 
Olig1 and Olig2.  Shh is both necessary and sufficient for the expression of these genes in the developing 
CNS in vivo [53, 54].  Additionally, both Olig1 and Olig2 are required for oligodendrocyte differentiation as 
genetic knock-out of both genes results in decreased oligodendrocyte differentiation [48, 49].  
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The Olig genes promote oligodendrocyte cell fate decisions by increasing expression of the SoxE 
group of high-mobility-group (HMG)-transcription factors, which includes the Sox8, Sox9, and Sox10 
transcription factors, in oligodendrocyte precursor cells.  Despite expression of all three transcription 
factors in developing and mature oligodendrocytes, each has a functionally distinct role in 
oligodendrocyte cell fate specification.  Genetic ablation of Sox10 in developing embryos results in the 
accumulation of neural progenitor cells and the loss of oligodendrocytes during embryogenesis, 
demonstrating a requirement for this transcription factor in the terminal differentiation of oligodendrocytes 
[55].  In contrast, targeted loss of Sox9 in NSCs leads to the formation of more astrocytes and fewer 
oligodendrocytes, indicating that this transcription factor is necessary for pro-glial cell fate specification 
[56].  Lastly, although Sox8 is expressed in developing and mature oligodendrocytes, genetic loss of this 
transcription factor does not alter the formation of oligodendrocytes in the CNS, indicating that Sox8 is 
dispensable for oligodendrocyte differentiation [57].  Functionally, these transcription factors are 
responsible for the expression of oligodendrocyte-specific genes.  In zebrafish, Olig1 cooperatively binds 
to Sox10 in order to express myelin basic protein, a key component for myelin sheath formation [58].  
Similarly, genetic loss of either Sox9 or Sox10 in oligodendrocyte progenitor cells results in decreased 
expression of the PDGF receptor alpha (PDGFRα), an oligodendrocyte protein responsible for cell 
survival and migration [59].  Overall, this establishes a clear regulatory mechanism whereby Shh 
expression specifies oligodendrocyte cell fate through Olig and SoxE transcription factor-mediated 
expression of oligodendrocyte-specific genes.  
 
BRAIN DEVELOPMENT GONE AWRY: THE RASOPATHIES 
 Normal development of the CNS is disrupted in several neurodevelopment disorders, providing 
insight into the regulatory mechanisms most critical for normal brain development.  In particular, the 
neuro-cardio-facio-cutaneous syndromes comprise a family of related neurodevelopmental disorders 
resulting from hyperactivating mutations that affect the RAS signaling pathway (Figure 1.4).  These 
disorders are more commonly referred to as RASopathies, underscoring the importance of the RAS 
pathway in regulating normal neural development.  Several shared clinical features characterize the 
RASopathies, including neurodevelopmental defects (mental retardation, learning deficits, neurocognitive 
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delay), congenital heart defects, abnormal growth patterns (short stature, macroencephaly), and 
ectodermal defects (skin freckling, hyperkeratosis) [60].  A summary of these disorders, their causative 
mutations, and the CNS clinical features associated with each syndrome can be found in Table 1.1.  
Although the incidences of individual syndromes vary widely, as a whole the RASopathies occur in 
approximately 1 in 1,000 individuals [61].  Below is a brief summary of a subset of these disorders in the 
context of the CNS.  
 
Noonan Syndrome 
 Noonan Syndrome affects approximately 1 in 1,000-2,500 individuals and is characterized by 
craniofacial deformities, short stature, and congenital cardiac defects [62, 63].  In the CNS, individuals 
with this disorder are most commonly affected by memory deficits, and learning, speech, and motor 
delays [64-66].  The causative mutations underlying Noonan Syndrome increase activity of several 
components within the Ras signaling pathway.  A majority of individuals with Noonan Syndrome (>50%) 
harbor hyperactivating missense mutations in the PTPN11 gene [67].  This gene encodes the protein 
tyrosine phosphatase protein SHP2 responsible for propagating receptor tyrosine kinase signals to the 
RAS-activating guanine exchange factor (GEF) protein SOS1.  A smaller proportion of individuals (~20%) 
present with gain-of-function missense mutations in the SOS1 gene itself [68, 69].  These mutations 
cluster within the autoinhibitory region of the protein, leading to hyperactivation of SOS1 and subsequent 
hyperactivation of RAS and its downstream effector ERK [68].  Activating mutations have also been 
identified in the K-RAS and N-RAS family members, although both mutations occur rarely in Noonan 
patients (<5%) [70, 71].  Similarly, a rare set of mutations occurs in the RAF1 gene leading to the 
hyperactivation of the RAF1 effector protein operating downstream of RAS [72].  Taken together, these 
mutations aberrantly activate the RAS signaling pathway leading to disease progression and the CNS 
defects observed in individuals with Noonan Syndrome.    
 
Neurofibromatosis Type I 
 Neurofibromatosis Type 1 (NF1) represents another commonly occurring RASopathy with an 
incidence of approximately 1 in 3,000 individuals [73].  The clinical features of NF1 include café-au-lait 
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spots, axillary freckling, iris Lisch nodules, and a predisposition to peripheral nerve sheath tumor 
formation (neurofibromas) [62].  In the CNS, learning deficits and behavioral abnormalities are the most 
common features of NF1 with various cognitive deficits reported to occur in 81% of the population [74].  
Low-grade pilocytic astrocytomas often occur in children with NF1 and occur most frequently in the optic 
pathway, hypothalamus, and brainstem [75, 76].  The most common of these tumors, optic pathway 
gliomas, develop in approximately 15-20% of these individuals prior to age 10 [76, 77].  Unlike Noonan 
Syndrome, the NF1 disorder is caused by inactivating mutations within a single gene, NF1.  This gene 
encodes the protein neurofibromin, a GTP-ase activating protein (GAP) that normally functions to inhibit 
RAS activity [78-81].  As a result, loss of the NF1 gene leads to increased RAS activity [82].  
 
Costello Syndrome 
 A relatively rare RASopathy, individuals with Costello Syndrome may exhibit neurodevelopmental 
delays, cardiac and musculoskeletal defects, and craniofacial abnormalities [62, 83].  Individuals affected 
by this disorder are also predisposed to the formation of a variety of malignant and benign tumors, the 
most common of which include rhabdomyosarcoma and neuroblastoma [84].  Similar to NF1, the 
causative mutations of Costello Syndrome are found within a single gene (H-RAS), with the vast majority 
of these mutations occurring within codon 12 of the gene [85-87].  These mutations inhibit H-RAS 
GTPase activity, locking the protein in a hyperactive state and leading to aberrant RAS pathway 
signaling.  Moreover, preliminary phenotype-genotype correlational studies suggest that glycine to alanine 
mutations at this codon are associated with increased risk of malignant tumor formation relative to other 
Costello mutations [86].  Of the RASopathies, Costello Syndrome perhaps best demonstrates the 
consequence of hyperactivating mutations occurring within the RAS proteins themselves 
 
Legius Syndrome 
 Individuals affected by Legius Syndrome, a rarely occurring RASopathy, come to medical 
attention with symptoms resembling those of Noonan Syndrome and NF1, including neurocognitive 
impairments, café-au-lait spots, axillary freckling, and macrocephaly [62].  Similar to NF1 and Costello 
Syndrome, Legius Syndrome results from inactivating mutations within a single gene, SPRED1, encoding 
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a regulatory protein that mediates RAS activity and its activation of the downstream MEK/ERK effector 
pathway [88, 89].  Loss-of-function mutations within the SPRED1 and related SPRY family of proteins 
have not been reported in other neurodevelopmental disorders, leading to the designation of Legius 
Syndrome as a distinct disorder within the RASopathy family [88]. 
 
Cardio-Facio-Cutaneous Syndrome 
 A final, rarely-occurring disorder in the RASopathy family, Cardio-Facio-Cutaneous (CFC) 
Syndrome has overlapping features with Noonan Syndrome, Costello Syndrome, and NF1.  These 
include cardiac deficiencies, ectodermal and musculoskeletal abnormalities, and short stature [62].  In the 
CNS, CFC Syndrome patients may present with learning disabilities and motor and speech 
developmental delays.  Unlike many of the disorders discussed already, CFC Syndrome is primarily 
caused by mutations affecting hyperactivation of RAS downstream effector proteins.  The majority of 
these mutations lead to hyperactivation of the B-RAF protein, although mutations in K-RAS, MEK1, and 
MEK2 have also been reported in this patient population [90-92]. 
 
THE RAS SIGNALING PATHWAY 
Canonical Ras Signaling 
First identified in rat sarcoma cells, the 21 kDa small-GTPase protein RAS is the key transducer 
of growth factor signaling to downstream effector proteins. Specifically, RAS functions as a small-
molecule switch by alternating between active, guanosine triphosphate (GTP)-bound and inactive, 
guanosine diphosphate (GDP)-bound states to transmit growth factor signals (Figure 1.4).  RAS is 
activated by the exchange of bound GDP with a new GTP molecule, which causes conformational 
changes in the RAS protein.  This process is facilitated by a family of GEF proteins that facilitate GDP 
release and GTP binding.  Although one GEF protein, SOS, is most commonly implicated in RAS protein 
activation at the plasma membrane, other GEFs such as RAS guanosine nucleotide releasing protein 
(RasGRP1) can similarly activate RAS at locations distinct from the plasma membrane.  RAS inactivation 
occurs by hydrolysis of the bound GTP to GDP, which remains bound to RAS.  Although RAS has a slow 
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intrinsic GTPase activity on its own, this activity is greatly enhanced in the presence of GTPase-activating 
proteins (GAPs), such as p120GAP and neurofibromin, which inactivate RAS. 
One mechanism of activating the RAS signaling pathway requires extracellular growth factor 
binding to receptor tyrosine kinase (RTK) proteins.  A variety of growth factors are known to bind RTKs, 
including EGF, FGF, and nerve growth factor (NGF).  Upon binding at the RTK extracellular domain, 
these growth factors promote homodimerization of the RTK proteins, which leads to autophosphorylation 
of the RTK intracellular domains.  Within the cell, several adapter proteins, such as SHC, SHP2, and 
GRB2, contain SH2 domains specific for binding to the phosphorylated RTK intracellular domains.  
Simultaneously, these adaptor proteins bind the RAS-GEF protein SOS which, when bound to the RTK 
complex, activates RAS.  Once activated, RAS functions to regulates cell growth and differentiation via 
two canonical downstream pathways, including through the downstream effector proteins 
phosphatidylinositol 3-kinase (PI3K) and the RAF/MEK/ERK signaling cascade [93, 94].   
  
Structure of the RAS Genes 
The RAS superfamily of genes consists of related small GTPase proteins that share sequence 
homology with the RAS genes.  This family is divided into several subgroups, including the RAS, RHO, 
ARF, RAN, and RAB subfamilies.  Within the RAS subfamily, there are multiple related forms of RAS 
found in mammals (Figure 1.5).  Three closely related variants of this subfamily – H-RAS, K-RAS, and N-
RAS – are considered to be the classical RAS proteins and are the focus of this thesis.  Other RAS 
subfamily members are evolutionarily diverged from these classical RAS proteins and include E-RAS 
(expressed in embryonic stem cells), R-RAS (endothelial cells, vascular smooth muscle cells), and M-
RAS (muscle cells and brain hippocampus, cerebellum) [95-98].  Of the classical RAS genes, both H-
RAS (full name: Harvey-RAS) and K-RAS (Kirsten-RAS) were initially identified as the causative effectors 
of tumor growth upon their discovery in rat sarcoma virus in the 1960’s [99, 100].  K-RAS is expressed as 
two alternatively spliced variants (K-RAS4A, K-RAS4B), however in this thesis, K-RAS refers to the 
ubiquitously expressed K-RAS4B isoform.  N-RAS (Neuroblastoma-RAS) was initially isolated from the 
SK-N-SH neuroblastoma cell line and was capable of transforming NIH 3T3 fibroblasts [101].  
Subsequent genetic mapping studies revealed that these classical RAS genes reside on different 
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chromosomal loci in humans: 11p (H-RAS), 12p (K-RAS), and 1p (N-RAS) [102-105].  In mice, the RAS 
genes also reside on different chromosomes (H-RAS on chromosome 7, K-RAS on chromosome 6, N-
RAS on chromosome 3), indicating that mouse and human Ras genes diverged from one another 
relatively recently, as demonstrated by orthologous gene sequence analysis [106].  Despite their 
divergent genetic locations, the RAS molecules share 85% nucleotide sequence homology, suggesting 
that these genes diverged from a single common Ras gene [107].  The conserved region of the RAS 
genes encodes the GTP-binding region (a phosphate-binding loop [P-loop]) and the switch I and switch II 
regions that direct RAS binding to effector proteins (Figure 1.6). The remaining 15% of the nucleotide 
sequence encodes a 25 amino acid, C-terminal hypervariable region (HVR) that differs between the RAS 
genes and is thought to underlie the differential post-translational processing, plasma membrane 
localization, and signaling capacity of the encoded RAS proteins.   
 
Post-Translational Processing and Trafficking of the Ras Molecules 
All RAS molecules undergo extensive, multi-step post-translational modification to correctly traffic 
and localize RAS to the inner leaflet of the plasma membrane and endomembranes such as the Golgi 
and the endoplasmic reticulum (ER) (Figure 1.7).  Without these modifications, the RAS molecules are 
hydrophilic with little affinity for the membranes where they ultimately localize.  A series of lipid 
modifications is therefore required to convert the HVR to a hydrophobic region capable of anchoring 
these molecules within lipid membranes.  RAS processing is initiated at a CAAX (C=cysteine, A=aliphatic 
amino acid, X=any amino acid) motif present at the carboxy-terminal portion of the HVR.  Following 
translation, a hydrophobic isoprenyl group is added to the cysteine of the CAAX motif (prenylation) via the 
farnesyltransferase enzyme.  This modification causes RAS to localize at the cytosolic surface of the ER 
for further modification steps [108].  Once at the ER, the RAS converting CAAX endopeptidase 1 (RCE1) 
enzyme cleaves the AAX tripeptide from the CAAX motif, allowing for subsequent methylation of the 
newly exposed α-carboxyl group (C186) by the isoprenylcysteine carboxyl methyltransferase (ICMT) 
enzyme [109-111].  Here, the RAS molecules begin to diverge in their processing.  In this regard, K-RAS 
is more efficiently methylated by ICMT than its H-RAS and N-RAS counterparts [112].   
	   16 
The remaining upstream HVR sequence provides secondary signals that direct additional 
differential processing and trafficking of the Ras molecules (Figure 1.6) [113].  Two cysteines on H-RAS, 
C181 and C184, are the target of a covalent addition of fatty acids (palmitoylation) by the RAS 
palmitoyltransferase enzyme.  N-RAS is similarly palmitoylated, but only at C181 [111].  Based on site 
mutagenesis studies, palmitoylation at these cysteines is required for trafficking of these proteins from the 
ER to the plasma membrane [112].  Using GFP-tagged molecules of H-RAS or N-RAS, two studies 
observed that these RAS molecules accumulate at both the Golgi and the plasma membrane, suggesting 
that H-RAS and N-RAS traffic to the plasma membrane via the Golgi apparatus [112, 114].  In the 
presence of Brefeldin A (BFA), a chemical agent that disrupts the Golgi membrane, there was significant 
loss of H-RAS-GFP or N-RAS-GFP localization at the plasma membrane.  This confirms that both H-RAS 
and N-RAS transit from the ER to the plasma membrane in a Golgi-dependent manner.   
In contrast, K-RAS is not palmitoylated but instead contains a polybasic, lysine-rich sequence 
within the HVR that confers a net positive charge at its C-terminus and targets K-RAS directly to the 
plasma membrane (Figure 1.7) [115].  Unlike H-RAS and N-RAS, GFP-tagged K-RAS is found at the 
plasma membrane but not at the Golgi, suggesting that K-RAS traffics to the plasma membrane without 
further processing within the Golgi.  In support of this hypothesis, BFA treatment of cells does not reduce 
K-RAS-GFP accumulation at the plasma membrane, indicating that K-RAS transits to the plasma 
membrane in a Golgi-independent manner [114].   
The exact mechanism underlying K-RAS trafficking to the plasma membrane remains unclear, 
however, several possible mechanisms have been proposed.  First, given the net charge difference 
between the positively charged K-RAS HVR and the negatively charged plasma membrane, it is possible 
that plasma membrane trafficking occurs down an electrostatic gradient.  Evidence in support of this 
theory arises from mutational studies of the K-RAS HVR that converted subsets of lysine residues to 
glutamine residues in order to alter the amphipathic and charge properties of this portion of the K-RAS 
molecule [116].  Mutations that maintained the +6 positive charge of normal K-RAS and the amphipathic 
properties of the HVR were most successful at correctly localizing GFP to the plasma membrane.   
Further evidence for charge-driven trafficking is found in the presence of the anionic lipid-binding agent 
neomycin, which reduces K-RAS-GFP association with the plasma membrane.  This suggests that the 
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positively-charged K-RAS HVR requires negatively charged lipids within the membrane to direct its 
movement from the ER to the plasma membrane.  A second mechanism may function by trafficking K-
RAS to the plasma membrane in a microtubule-dependent manner.  Support for this theory is based on 
the high affinity of prenylated and methylated K-RAS molecules for microtubules within the cell [117, 118].   
In the presence of the chemical agent taxol, which stabilizes the otherwise dynamic microtubule 
structures, K-RAS localization to the plasma membrane is greatly reduced [114, 118].  Taxol 
administration has no effect on the localization of H-RAS-GFP at the plasma membrane, indicating that K-
RAS trafficking alone occurs in a microtubule-dependent manner.  A third and final potential mechanism 
suggests that K-RAS trafficking to the plasma membrane could be facilitated by a chaperone protein.  
This mechanism is well established for the RAS-related RHO GTPase protein which is trafficked to the 
plasma membrane by the RHO guanine nucleotide dissociation inhibitor (RHOGDI) chaperone protein 
after RHO geranylgeranylation and methylation at the ER [119].  On its own, RHO is rapidly degraded by 
cytosolic proteasomes.  However, RHOGDIs sequester RHO in the cytosol and traffic these proteins 
directly to the plasma membrane.  The prenyl binding protein PDEδ is proposed to function similarly for K-
RAS by chaperoning its transport from the ER to the plasma membrane and by ensuring the correct 
localization of K-RAS molecules within plasma membrane microdomains [120].  Given the high 
occurrence of oncogenic K-RAS signaling in tumor progression, the K-RAS-PDEδ interaction has recently 
become the subject of small molecule inhibitor development.  Indeed, disruption of this interaction leads 
to the localization of K-RAS to endomembrane domains and disrupts downstream K-RAS signaling [121].  
Taken together, it is clear that trafficking of K-RAS to the plasma membrane occurs in a more complex 
manner than that of H-Ras and N-RAS trafficking.  These early differences in HVR processing and 
plasma membrane trafficking underscores the importance of these processes in conferring functional 
differences on each of the individual RAS molecules. 
 
Microlocalization within the Plasma Membrane 
One of the important consequences of differential RAS processing and trafficking is the capacity 
for the structurally similar RAS molecules to trigger distinct signaling cascades from unique domains 
within the plasma membrane.  The plasma membrane consists of a heterogeneous mix of cholesterols, 
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lipids, and proteins arranged in lipid and non-lipid raft domains that laterally segregate the RAS molecules 
within the plasma membrane (discussed below).  Growing evidence indicates that RAS molecule 
signaling in these domains occurs primarily from nanoclusters—signaling domains approximately 6-20nm 
in diameter and containing as few as 6-8 RAS proteins per cluster [122].  Nanocluster formation is 
dictated by several factors, including plasma membrane and cytoskeleton composition, RAS HVR 
interaction with the plasma membrane, and effector molecule recruitment to individual signaling domains.  
In this regard, RAS nanocluster formation is dependent on the cholesterol composition of the plasma 
membrane.  Both H-RAS-GDP and N-RAS-GTP cluster formation is cholesterol-dependent while the 
formation of H-RAS-GTP, N-RAS-GDP, and K-RAS-GTP nanoclusters are all cholesterol-independent 
[123].  Moreover, immunogold labeling of active RAS proteins within intact plasma membrane sheets 
revealed a differential dependence on an intact actin cytoskeleton for K-RASG12V, but not H-RASG12V, 
nanoclusters indicating a role for cytoskeleton composition in nanocluster formation [122].  The 
structurally distinct HVR sequences of the RAS molecules also drive nanocluster formation.  This is 
exemplified by the stabilization of active H-RAS signaling nanoclusters by the cytosolic lectin protein 
galectin-1.  Upon activation at the plasma membrane, H-RAS signaling nanoclusters are stabilized by 
galectin-1 binding at the farnesyl moiety within the H-RAS HVR [124].  Apart from simply stabilizing these 
signaling domains, H-RAS-galectin-1 interactions also direct H-RAS signaling to Raf-1 but not PI3K 
downstream effector proteins [125].  Similarly, the Sur-8 and SPRED1 proteins have also been reported 
to modulate RAS signaling to downstream effector proteins at the plasma membrane, suggesting an 
important role for these proteins in facilitating the formation of transient RAS-effector signaling complexes 
[89, 126].  Recent findings demonstrate that nanocluster formation can occur in a manner directly 
proportional to growth factor input signals, indicating that functionally, the formation of RAS nanoclusters 
ensures the fidelity of ligand input signaling to the downstream signaling cascades [127].  Taken together, 
the differential signaling capacity of the RAS molecules is therefore dependent upon lateral segregation of 
the RAS molecules and multiple layers specifying the membrane and effector composition of nanocluster 
signaling domains within the plasma membrane.  This merits further discussion in the context of how the 
individual RAS molecules themselves segregate within the plasma membrane prior to nanocluster 
formation.  
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Comparison of H-RAS and K-RAS membrane localization indicates that these molecules occupy 
distinct portions of the membrane.  Of the three RAS molecules, the localization of H-RAS within the 
plasma membrane has been best characterized using GFP-tagged H-RAS molecules and immunogold 
electron microscopy techniques.  Early work demonstrated that H-RAS localization is dynamic, occupying 
both lipid raft and non-lipid raft portions of the plasma membrane [128, 129].  Trafficking between these 
domains is dependent on the activation state of H-RAS.  Inactive, GDP-bound H-RAS is associated with 
lipid raft portions of the plasma membrane, while active, GTP-bound H-RAS transits to non-lipid raft 
portions of the membrane [129].  The underlying mechanism of this transition relies on three key regions 
of the H-RAS protein.  The CAAX motif and the two palmitoyl sites (cysteines 181, 184) within the HVR 
have a high affinity for lipid raft domains, thereby localizing H-RAS-GDP to these domains by default 
[130].  However, a linker domain between the HVR and N-terminal portion of the protein exhibits affinity 
for non-lipid raft portions of the membrane.  Once GTP-bound, the N-terminal domain of H-RAS exerts a 
repulsive force on lipid rafts which, in combination with the linker domain, triggers trafficking to non-lipid 
raft portions of the membrane.  Here, the lectin protein galectin-1 stabilizes H-RAS-GTP in the non-lipid 
raft portion of the membrane and facilitates formation of H-RAS signaling nanoclusters [128].  Increasing 
amounts of galectin-1 increases the stability of these H-RAS signaling clusters and can increase the 
signaling output from these clusters [131].  
In contrast, K-RAS localizes exclusively in non-lipid raft domains of the plasma membrane, 
although in areas distinct from those occupied by active H-RAS [128, 129, 132].  Owing to the poly-lysine 
sequence within the HVR, K-RAS localization requires anionic lipids to associate within the plasma 
membrane, as the C-terminal region of K-RAS has a low affinity for neutrally-charged lipids in the 
membrane [133].  Despite this dependence, K-RAS does not appear to associate with any specific 
anionic lipids.  In order to form signaling nanoclusters, K-RAS relies on an intact actin cytoskeleton, the 
loss of which appears to be especially deleterious to activated K-RAS signaling [122].  K-RAS clustering 
also requires farnesylation of the HVR, as geranylgeranylation (an alternative prenylation step) does not 
allow for correct clustering of K-RAS in non-lipid raft portions of the membrane [128].  
To date, few studies have focused on the membrane localization of N-RAS.  Recent biochemical 
studies using a series of modified N-RAS lipid anchor motifs demonstrate that N-RAS occupies fluid-like, 
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non-lipid raft domains within the plasma membrane [134, 135].  Localization to the plasma membrane and 
subsequent activation of N-RAS requires that this molecule be palmitoylated at cysteine 181 within its 
HVR [136].  Following activation at the plasma membrane, recent studies suggest that this facilitates N-
RAS clustering in lipid raft portions of the membrane, which precedes depalmitoylation and retrograde 
transport of N-RAS to the Golgi [137].  As such, this provides a mechanism by which active N-RAS may 
accumulate at both the plasma membrane and at endomembranes (Golgi and ER) as is discussed further 
in the next section. 
 
Differential Signaling of the RAS Molecules 
Activation of the RAS molecules occurs at multiple domains within the cell depending on the RAS 
family member and its subcellular localization.  While the majority of Ras activation occurs at the plasma 
membrane, there is evidence that active H-Ras and N-Ras can also be found at the Golgi and the ER 
[138, 139].  This reflects the capacity for both molecules to transit from the plasma membrane to the Golgi 
by recycling endosomes upon HVR depalmitoylation [136, 140].  The differential activation of the Ras 
molecules in the cell may also reflect location-specific sensitivity to GEFs.  While Ras is activated by a 
variety of GEFs at the plasma membrane, only RasGRP activates Ras at the Golgi [141, 142].  In 
combination, the differential localization and sensitivity to GEF activity provides mechanisms by which the 
Ras molecules can have divergent signaling capacities. 
Two signaling pathways that operate downstream of active RAS have been especially well 
characterized in the literature to date.  In the first pathway to be discovered, the Raf family of 
serine/threonine kinase proteins was demonstrated to directly bind to Ras in its active, GTP-bound form 
[143-146].  Although Ras itself cannot function as a kinase, Ras reduces Raf autoinhibition upon binding 
to the Ras binding domain (RBD) within the N-terminus of the Raf protein [147, 148].  Subsequently, Ras 
escorts Raf to the plasma membrane for subsequent activation by a number of kinases, including Src and 
protein kinase C (PKC) [94, 149].  There are three members of the RAF kinase family, RAF-1 (C-RAF), A-
RAF, and B-RAF, all of which can be activated by the H-RAS, K-RAS, and N-RAS molecules [150].  
However, only B-Raf activity is exclusively dependent on Ras-mediated activation as both C-Raf and A-
Raf can be activated by Src in the absence of Ras [151].  Upon activation, Raf activates Mek1 and Mek2 
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by phosphorylating serines 217 and 221 on these proteins [152].  Subsequently, Mek1/2 activates the 
Erk1 and Erk2 effectors by phosphorylating threonine 202 and tyrosine 204 on these proteins [153].  This 
phosphorylation cascade is most often associated with canonical Ras signaling and is most often 
implicated in regulating cell growth, differentiation, and apoptosis.  
Subsequent studies identified another downstream effector protein, phosphatidylinositol 3-kinase 
(PI3K), that binds active Ras in a Raf-independent manner [154].  Active PI3K phosphorylates 
phosphatidylinositol (4,5)-bisphosphate (PIP2), converting the protein to the secondary messenger protein 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3).  PIP3 binds to proteins containing a pleckstrin homology 
(PH) domain such as phosphoinositide-dependent kinase 1 (PDK1) and Protein Kinase-B (AKT).  Upon 
binding, PIP3 facilitates PDK1/Akt trafficking to the plasma membrane, where Akt is subsequently 
activated by phosphorylation at threonine 308 [155, 156].  Once activated, Akt activates the mammalian 
target of rapamycin (mTOR) complex 1 (mTORC1), a key signaling complex in the regulation of gene 
expression, protein translation, and cell proliferation.  To do so, mTORC1 increases protein translation by 
phosphorylating (activating) the p70 S6 kinase ribosomal protein and the eukaryotic initiation factor 
binding protein 4E-BP1 [157, 158].   
These conventional pathways provide a framework by which to understand how RAS might 
regulate cell proliferation and differentiation functions.  However, not every RAS molecule signals through 
these conventional pathways in the same way.  As an example, K-Ras and H-Ras exhibit different 
capabilities of activating the Raf-1 and PI3K effector proteins at the plasma membrane.  Relative to H-
Ras, K-Ras is better able to recruit and subsequently activate Raf-1 at the plasma membrane [159].  In 
contrast, H-Ras is a more potent activator of PI3K than K-Ras.  This differential capacity to signal to 
different downstream effector proteins is a direct result of different HVR sequences on the Ras molecules.  
Shortening of the H-Ras HVR to more closely resemble the K-Ras HVR results in improved Raf-1 
recruitment to the plasma membrane by H-Ras.  K-Ras also retains more Raf-1 within its signaling 
nanoclusters at the plasma membrane relative to H-Ras, thereby allowing K-Ras-GTP to induce 
Raf/Mek/Erk signaling more potently than H-Ras-GTP [160].  The location of individual Ras molecules is 
also critical to their differential signaling capacity.  Activated forms of both H-Ras and N-Ras are found at 
the Golgi and ER, owing to accumulation during posttranslational processing and retrograde transport 
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from the plasma membrane [139, 161, 162].  Although H-Ras has a diminished ability to activate Raf-1 at 
the plasma membrane compared to K-Ras, H-Ras can activate Raf-1 and downstream Erk activity from 
the ER, leading to subsequent transformation of cells [139].  Taken together, these data suggest a model 
in which the biological effects of increased RAS signaling are dependent upon the specific RAS molecule 
in question as well as its location within the cell. 
In addition to PI3K and RAF, RAS can also activate a variety of other signaling effector proteins 
including those involved in cell growth and function (PKC-ζ, RAC, β-catenin), cell fate decisions (PKC-γ, 
PDK1), and oncogenesis (JNK, RAN GTPase) [163-168].  It is likely that these effector proteins will also 
demonstrate differential susceptibility to activation by the individual Ras molecules.  In fibroblasts, K-Ras, 
but not H-Ras, activation leads to increased activation of the small GTPase protein Rac, as demonstrated 
by increased Rac-GTP in these cells [167].  Together, the variety of downstream effector proteins coupled 
with the potential variability of individual RAS molecules to activate these effectors suggests a robust 
infrastructure by which RAS can regulate cell growth and function.   
Despite a number of in vitro studies comparing the impact of Ras molecule activation on cell 
function, there are few studies comparing the consequence of Ras molecule hyperactivation in vivo.  
Recently, Haigis, et al., compared the consequences of activating individual Ras molecules in a mouse 
model of colon cancer [169].  Oncogenic mutations in K-RAS (K-RASG12D) occur in approximately 50% of 
colon cancers, whereas N-RAS mutations (N-RASG12D) occur only rarely (~5%).  In order to determine 
how each hyperactivated Ras molecule impacts the progression of colon cancers, genetically engineered 
mice were generated which, in cells expressing Cre recombinase, express a hyperactivated copy of Ras 
that is transcribed under the control of the endogenous Ras promoter.  These mice were also used in the 
current thesis and a full description of the constructs can be found in Chapter 2: Materials & Methods.  
Using a colon-specific promoter to drive Cre recombinase (and hyperactive Ras) expression in these 
cells, differential biological effects upon Ras molecule hyperactivation were observed.  K-Ras 
hyperactivation led to hyperproliferation of the colon epithelium in a Mek-dependent manner.  Conversely, 
N-Ras hyperactivation did not alter the growth of the epithelium but conferred increased resistance of 
these cells to programmed cell death (apoptosis).  This study was the first to provide evidence of 
differential biological function of the Ras molecules in vivo and provides an important foundation for 
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studies comparing Ras molecule hyperactivation, as in the current thesis.  Additionally, this work yielded 
an important tool for studying Ras molecule hyperactivation in vivo in a biological relevant, endogenous 
expression context.  
 
Activating Ras Mutations 
A relatively high proportion of cancers (30%) are known to result directly from activating RAS 
mutations [170].  Reflecting the differential capacities of the RAS molecules, mutations are not uniformly 
distributed across the individual RAS molecules.  An analysis of the Catalog of Somatic Mutations in 
Cancer (COSMIC) database identifies K-RAS as the most frequently mutated in cancers (22% of all 
tumors), followed by N-RAS (8%) and H-RAS (3%) [170].  While this partially results from the differential 
signaling capacity of the RAS molecules, this may also reflect the differential contributions of each RAS 
molecule to total RAS expression.  A previous analysis of multiple cancer cell lines determined that K-
RAS is more highly expressed than either its N-RAS or H-RAS counterparts [161].  Nevertheless, the 
RAS molecules are commonly associated with certain families of cancers.  K-RAS mutations are more 
commonly associated with cancers in tissues of endodermal origin, (lung, pancreas, colon) while N-RAS 
mutations occur most commonly in hematopoietic (neural crest-derived) disorders [171-174]. 
Aberrant RAS activation results from mutations at only three sites within the RAS genes: codons 
12, 13, and 61.  Although mutations at all three sites have been documented for each RAS molecule, the 
frequency of mutations at each site varies from molecule to molecule.  For example, 80% of activating 
mutations in K-RAS occur at codon 12 while 60% of N-RAS mutations occur at codon 61 with only 35% 
occurring at codon 12 [170].  In contrast, activating mutations in H-RAS occur in relatively equal 
proportions at both codons.  The frequency of activating mutations at these sites lies in the intrinsic 
requirement for the encoded amino acids in normal RAS-GAP function.  The catalytic domain of RAS, N-
terminal to the HVR and conserved between the RAS molecules, contains the amino acid sequences 
required for the intrinsic GTP-ase activity of RAS.  Of particular functional importance is the role of the 
switch I (amino acids 25-40) and switch II (amino acids 57-75) regions within the catalytic domain which 
undergo significant conformational changes during RAS activation/inactivation (Figure 1.6) [175-177].  A 
resolved crystal structure of AlF3-stabilized H-Ras in its transition state reveals the function of the mutated 
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sites in GTP hydrolysis.  In its transition state, an arginine residue from the GAP protein (arginine 789 on 
p120GAP) is inserted into the Ras active site to neutralize developing charges and stabilize the Ras switch 
II region [178].  This also stabilizes Ras glutamine 61, allowing the residue to participate in catalysis of the 
GTP γ-phosphate at the Ras active site.  Of particular interest is the close proximity of Ras glycine 12 
within Van der Waals distance of both Ras glutamine 61 and GAP arginine 789 within the Ras active site.  
This proximity precludes the addition of side chains, even one as small as alanine, without significant 
functional disruption to the Ras active site.  Presumably, this constraint also applies to Ras glycine 13, 
which is found in equally close proximity to these residues in the active site.    
The complexity of differential RAS signaling has frustrated the development of drug therapies 
aimed at reducing aberrant RAS pathway hyperactivation.  Preliminary studies aimed at blocking Ras 
processing and subsequent localization to the plasma membrane suggested that farnesyltransferase 
inhibitors (FTIs) could therapeutically abrogate hyperactivation of all three RAS molecules [179, 180]. 
Despite a strong biological foundation in support of moving these inhibitors to clinical trials, phase I trials 
using FTIs in the context of NF1 plexiform neurofibromas yielded a limited tumor response to the drug 
[181].  While in theory all RAS molecules should be inhibited by FTIs, in vitro biochemical studies 
comparing the efficiency of FTI treatments revealed that RAS processing is differentially inhibited across 
the three RAS molecules [182].  In line with preclinical results, H-RAS processing is successfully inhibited 
in the presence of FTIs.  However, both N-RAS and K-RAS can bypass this FTI inhibition by alternatively 
undergoing geranylgeranylation and subsequent processing and trafficking to the membrane.  A second 
pharmacological agent, lovastatin, primarily inhibits cholesterol biosynthesis but also inhibits RAS 
prenylation [183, 184].  To date, preclinical and clinical trials of lovastatin have focused on correcting 
learning and behavioral deficits in individuals affected by NF1 with mixed success [185-187].  Given the 
differential processing, localization, and signaling capacity of the individual RAS molecules, future 
therapeutic treatments will need to consider taking a more directed approach to inhibit RAS pathway 
hyperactivation.  In place of broad scale treatments such as FTIs and lovastatin, novel approaches will 
target individual downstream effector pathways as a more efficient and precise means by which to inhibit 
hyperactivation of the individual RAS molecules. 
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SUMMARY AND SIGNIFICANCE 
 The specification of NSCs towards neuron, astrocyte, and oligodendrocyte cell fates is a closely 
regulated process necessary to ensure normal brain development.  Disruptions in the signaling pathways 
described in this section, as demonstrated by genetic overexpression and knock-out studies, can radically 
skew NSC differentiation towards one lineage versus another to alter the overall composition of the brain.  
The RASopathy family of neurodevelopmental disorders further underscores the consequence of aberrant 
hyperactivation of a single regulatory pathway on normal brain development, resulting in abnormal neural 
functions, including learning deficits and behavioral abnormalities.  Despite the clear importance of this 
signaling pathway in brain development, the mechanisms underlying RAS pathway hyperactivation and 
its impact on brain development are incompletely characterized.  This is especially relevant to the function 
of NSCs, which give rise to the majority of cell types in the brain.  Given the capacity for the three RAS 
molecules (H-RAS, K-RAS, N-RAS) to localize and signal differently upon activation, the contribution of 
each RAS molecule must be characterized in the context of brain development.  In this thesis, we 
leverage a novel series of genetically-engineered mouse (GEM) strains to characterize the consequence 
of hyperactivation of the individual Ras molecules on brain development and the cell-intrinsic properties of 
NSCs.  This work has important implications for the development of therapeutic approaches designed to 
target aberrant RAS pathway hyperactivation in the brain.   
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Figure 1.1. Timeline of mammalian brain development.  The NSC pool differentiates into mature cell 
types during both embryonic and postnatal brain development in a temporally-regulated manner.  
Neurons develop first beginning at embryonic day 10.5 (E10.5) in the mouse.  Astrocytes (E15.5) and 
oligodendrocytes (postnatal day 1 (P1)) develop afterward to support these newly formed neurons.  The 
timeline of mammalian brain development was extensively characterized in the rat brain, correlating to the 
timepoints in parentheses. 
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Figure 1.2. Cell fate specification during the neurogenic period of brain development.  From E10.5-
E15.5, neurogenesis is specified by both cell-intrinsic and cell-extrinsic factors.  At the genetic level, the 
transcription factors Ngn1, Ngn2, Mash1, and Math3 promote transcription of neuronal genes.  BMP 
signaling promotes neurogenesis directly, while MEK/ERK5 may mediate autocrine pro-neurogenic 
signals via the C/EBP transcription factor.  At this stage, astrocyte cell fate decisions are inhibited by the 
pro-neuronal transcription factors Mash1 and Math3 and by CpG methylation (Me) in the promoter region 
of astrocyte-specific genes.  Ngn1 also sequesters the pro-astrocytic STAT transcription factor from 
astrocytes-specific genes.  
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Figure 1.3.  Cell fate specification during the gliogenic period of brain development.  Gliogenic 
signals proceed predominantly through the gp130 family of membrane receptors (in turquoise).  
Cardiotrophin-1 (CT-1) and Notch promote gliogenesis based on signals from neurons and surrounding 
neuroblast progenitors, respectively.  Leukemia inhibitory factor (LIF) and ciliary neurotophic factor 
(CNTF) activate STAT transcription factors via the Janus kinase (JAK) protein.  BMP promotes Smad1 
binding at astroglial gene promoters, which synergistically promotes astroglial gene transcription with 
STAT via the transcriptional coactivator protein P300.  BMP also promotes expression of the Id2, Id3, and 
Hes5 transcription factors, which inhibit the action of the pro-neurogenic transcription factors Mash1 and 
Ngn1. 
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Figure 1.4. The RAS signaling pathway.  The small G-protein RAS mediates downstream signaling 
initiated by growth factor (GF) binding at receptor tyrosine kinase (RTK) membrane proteins.  RAS 
mediates these signals by transitioning between an active GTP-bound state and an inactive GDP-bound 
state, with activation assistance from the guanine exchange factor (GEF) SOS and inactivation facilitated 
by the GTPase activating protein (GAP) neurofibromin.  There are three RAS molecules expressed in the 
mammalian brain that, when active, can promote cell proliferation and differentiation. 
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Figure 1.5. Genetic evolution of the RAS subfamily of genes.  The RAS protein subfamily is 
composed of related GTPase proteins that share sequence homology with the classical RAS proteins 
(blue), H-RAS, K-RAS, and N-RAS, which are the focus of this thesis.  As indicated by orthologous gene 
sequence analysis, the other members of this subfamily diverged from these classical RAS proteins and 
include E-RAS, expressed in embryonic stem cells, R-RAS, expressed in endothelial and smooth muscle 
cells, and M-RAS, expressed in muscle cells and some portions of the brain (hippocampus, cerebellum).  
Adapted from [188], points of genetic divergence are relative and not drawn to scale. 
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Figure 1.6. Genetic structure of the H-RAS, K-RAS, and N-RAS genes.  In humans, the three related 
RAS genes are located on separate chromosomes: H-RAS on 11p, K-RAS on 12p, and N-RAS on 1p.  
The first 165 amino acids are conserved among the three genes and encode the GTP-binding (P-loop) 
and effector-binding (switch I, II) regions of the RAS proteins.  The 25 amino acids at the C-terminus 
encode a hypervariable region (HVR) that underlies the differential processing, localization, and biological 
function of the RAS proteins.  The HVR contains a CAAX (C=Cysteine, A=aliphatic amino acids, X=amino 
acid) motif and secondary signals for divergent RAS molecule post-translational processing.  These 
secondary signals consist of a fatty acid addition (palmitoylation) at cysteines in the H-RAS (C181, C184) 
and N-RAS (C181) HVRs.  In contrast, the K-RAS HVR contains a poly-lysine (K) sequence that acts as a 
secondary signal.  Adapted from [189] and [188], numbers at the top indicate amino acid number (H-RAS 
and N-RAS are 189 amino acids in length, K-RAS is 188 amino acids in length).  
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Figure 1.7. Differential post-translational processing of the RAS molecules.  Upon translation, RAS 
molecules must undergo post-translational modifications to increase the affinity of the carboxy-terminus 
HVR for membrane localization.  Immediately following translation, all RAS molecules are located in the 
cytosol.  (1) To begin post-translational processing, the RAS molecules are farnesylated at the cysteine 
present within the CAAX motif at the C-terminus, localizing the protein to the endoplasmic reticulum 
where (2) the –AAX tripeptide is removed.  (3) The three RAS molecules undergo differential methylation 
by the isoprenylcysteine methyltransferase (ICMT) enzyme.  (4) H-RAS and N-RAS are trafficked through 
the Golgi apparatus where they undergo fatty acid modifications (palmitoylation).  (5) Following Golgi 
processing, H-RAS and N-RAS are trafficked to the plasma membrane while K-RAS is transported to the 
plasma membrane by an unknown, Golgi-independent mechanism. 
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Table 1.1.  Summary of neuro-cardio-facio-cutaneous syndromes. 
 
 
Disorder Incidence 
Mutated 
Genes 
Encoded 
Protein 
Occurrence 
within 
Disorder CNS Clinical Features 
Noonan Syndrome 1 in 1,000-2,500 
PTPN11 SHP2 ~50% memory deficits 
SOS1 SOS1 ~20% learning deficits 
K-RAS K-RAS <5% language development delay 
N-RAS N-RAS <5% motor delay 
RAF1 RAF1 rare   
Neurofibromatosis 
Type 1 1 in 3,000 NF1 Neurofibromin 100% 
learning disabilities 
behavioral abnormalities 
tumor predisposition 
(glioma) 
Costello Syndrome rare H-RAS H-RAS 100% neurodevelopmental delay 
Legius Syndrome rare SPRED1 SPRED1 100% mild neurocognitive impairment 
Cardio-Facio-
Cutaneous 
Syndrome 
rare 
B-RAF B-RAF 75% learning disabilities 
MAP2K1 MEK1 
25% 
motor delay 
MAP2K1 MEK2 speech delay 
K-RAS K-RAS rare   
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INTRODUCTION 
 
The formation of the mammalian brain is a carefully orchestrated process in which the sequential 
development of mature cell types ensures the formation of the functional neuronal signaling networks 
required for adult brain function.  In the mouse, brain development is initiated by the specification of 
neurons beginning at embryonic day 10.5 (E10.5), with a neuronal network forming through E15.5.  In 
order to support this newly formed neuronal network, glial astrocytes develop beginning at E15.5, 
followed shortly thereafter by the formation of insulating oligodendrocytes at birth (postnatal day 1 (PN1)).  
The close association between glial cells and neurons is necessary to ensure the health, viability, and 
signaling capacity of these neuronal networks [1].  Despite their divergent functions in the mature brain, 
all three cell types (neurons, astrocytes, and oligodendrocytes) arise from a single population of 
multipotent neural stem cells (NSCs).  The specification of these diverse cell fates requires targeted 
inputs to direct NSCs to develop into one mature cell type versus another.  This suggests an extensive 
array of signaling mechanisms is required to drive NSCs towards the correct cell fates at the correct 
developmental time point.  Indeed, at developmentally-restricted time points, cell-extrinsic signaling 
factors (cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), bone 
morphogenic protein (BMP)) and cell-intrinsic factors (Mash1, Math3, Ngn and Olig transcription factors) 
cooperate to induce NSC adoption of neuronal, astrocytic, and oligodendroglial cell fates [2-10]. 
Despite research aimed at dissecting the cell type-specific and time-specific regulation of cell fate 
specification in the brain, the importance of the RAS signaling pathway in NSCs during brain development 
is often overlooked.  The critical function of this pathway is most apparent in a family of neuro-cardio-
facio-cutaneous neurodevelopmental disorders that are characterized by abnormal RAS pathway 
signaling.  In the central nervous system (CNS), these disorders often manifest in the form of learning 
difficulties, behavioral abnormalities, and tumor predisposition [11].  In normal cells, the small GTP-ase 
protein RAS functions as a molecular switch by binding GTP in its active state and retaining GDP in its 
inactive state.  When activated, RAS-GTP functions in mediating growth factor signaling and promoting 
cell proliferation and differentiation.  In the neuro-cardio-facio-cutaneous syndromes, commonly termed 
RASopathies, normal RAS signaling is altered by germline mutations that lead to aberrant hyperactivation 
of RAS pathway signaling.  In the mammalian brain, there are three RAS molecules expressed, H-RAS, 
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K-RAS, and N-RAS.  Despite significant overlap in their genetic and amino acid sequences, variation at 
the C-terminal hypervariable region (HVR) directs differential post-translational processing, localization, 
and downstream effector protein signaling of the three RAS molecules [12-17].  These differences 
ultimately underlie differential biological functions of these molecules in vivo [18].       
 In this chapter, we hypothesized that hyperactivation of the RAS molecules at different 
developmental time points might have differential effects on progenitor cell growth and the resulting 
cellular composition of the adult brain.  To test this hypothesis, we used Cre-driver strains (BLBP-Cre and 
GFAP-Cre) to drive hyperactivated Ras expression in progenitor cells at two distinct developmental time 
points.  Our laboratory has previously developed and characterized a BLBP-Cre mouse to drive Cre 
recombinase expression in NSCs beginning at E9.5 [19].  Cre-expressing cells overlap with cells positive 
for the NSC marker brain lipid binding protein (BLBP) in the brain ventricular regions (a location of 
resident NSCs in the brain) and also express the BLBP marker when grown in neurospheres in vitro.  
Moreover, BLBP-Cre-expressing cells can undergo multi-lineage differentiation to give rise to neurons, 
astrocytes, and oligodendrocytes in vivo and in vitro.  Together, these data are consistent with the 
conclusion that BLBP-Cre is expressed in the brain NSC population.  In contrast, the GFAP-Cre mouse 
expresses Cre recombinase under a human promoter for glial fibrillary acidic protein (GFAP), a protein 
expressed in neuroglial progenitor cells and mature astrocytes.  Our laboratory has previously 
demonstrated that Cre recombinase expression is initiated beginning at E14.5 in neuroglial progenitor 
cells which give rise to mature neurons, astrocytes, and oligodendrocytes [20, 21].  Both strains of mice 
were intercrossed with GEM strains containing a Cre-dependent construct to drive expression of a 
hyperactivated copy of the individual Ras molecules from their endogenous promoters in Cre-expressing 
cells.  Here, we demonstrate that K-Ras, but not H-Ras or N-Ras, hyperactivation in NSCs at E9.5 leads 
to the formation of more astrocytes in the brainstem at approximately three weeks of age (PN18).  In 
contrast, activating any of these Ras molecules in NSCs at E14.5 does not result in gross abnormalities in 
glial cell formation in the three week old brain.  Characterization of the neuroglial progenitor cell 
population in K-RasBLBP mice at early developmental timepoints (E12.5, PN1) revealed that K-RasBLBP 
mice have more Sox2+ NSCs in the embryonic hindbrain at E12.5 and have more Olig2+ glial restricted 
progenitor cells in the brainstem of PN1 mice compared to littermate controls.  Taken together, these data 
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indicate a temporally-restricted role for Ras molecule hyperactivation in altering NSC function such that 
more astrocytes are formed in the mature brain.     
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MATERIALS AND METHODS 
 
Mice. Activated H-Ras, K-Ras, or N-Ras allele expression was induced in NSCs in vivo by intercrossing 
BLBP-Cre [19] or GFAP-Cre [20] mice with mice containing Lox-Stop-Lox (LSL)-H-RasG12V (Supplemental 
Figure S2.1; generated by Dr. Kevin Haigis), LSL-K-RasG12D [22], or LSL-N-RasG12D [18] constructs 
knocked into the respective Ras locus. All mice were maintained on a C57Bl/6 background under an 
approved animal studies protocol at Washington University.  
 
Immunohistochemistry. Brain tissues were collected at postnatal day 18 (P18). Prior to tissue 
harvesting, mice underwent intracardiac perfusion with Ringer’s solution containing lidocaine and heparin 
followed by 4% paraformaldehyde. Tissues were subsequently post-fixed overnight in 4% 
paraformaldehyde, and then in 70% ethanol prior to tissue processing and embedding.  Paraffin-
embedded tissues were sectioned at 6µm thickness using a Leica RM2125 RTS microtome (Leica 
Microsystems Inc., Buffalo Grove, IL). Antigen retrieval and appropriate primary antibodies (Supplemental 
Table S2.1) were applied overnight at 4°C prior to the addition of species-appropriate horseradish 
peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA). Images of the pons 
(Supplemental Figure S2.2) were acquired on a Nikon Eclipse E600 light microscope (Nikon Instruments 
Inc., Melville, NY) equipped with a Leica EC3 camera. Six to ten mice were collected per genotype along 
with appropriate matched littermate controls. 
 
Immunofluorescence. Brain tissue was collected following perfusion and fixation in 4% 
paraformaldehyde as described above.  After overnight fixation, these tissues were subsequently 
dehydrated in 30% sucrose for at least 24 hours prior to embedding in OCT mounting media (Sakura 
Finetek, Torrance, CA) and freezing at -80°C. All frozen tissues were sectioned on a Reichert-Jung 
Cryocut 1800 (Reichert Technologies, Depew, NY) cryostat into 10µm-thick sections. Primary antibodies 
(Supplemental Table S2.1) were applied overnight at 4°C followed by incubation with species-appropriate 
AlexaFluor® 488 or 568 secondary antibodies (Life Technologies) and counterstained with DAPI.  For 
postnatal tissues, images of the pons (Supplemental Figure S2.2) were acquired using a Nikon Eclipse 
TE300 inverted fluorescent microscope with a Photometrics CoolSnap EZ camera (Photometrics, Tucson, 
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AZ) and compared to littermate controls.  Marker-positive cells were quantified as a percentage of total 
DAPI+ cells.  For embryonic brain sections, images were acquired of the ventricular region of the 
hindbrain (the future site of the brainstem pons) using a Leica DFC 3000G camera.  Since the high 
density of cells in these images precluded quantification of total DAPI+ cells, marker-positive cells were 
normalized to the total tissue surface area in the images using Leica Application Suite Advanced 
Fluorescence software.  
 
Data Analysis. Unless noted otherwise above, tissue and cell staining images were quantitated using 
ImageJ image analysis software (U.S. National Institutes of Health).  GraphPad Prism 5 software 
(GraphPad Software, La Jolla CA) was used for all statistical analyses in this study.  Specifically, outlier 
values were determined using the Grubbs outlier test and statistical significance (*p<0.05, **p<0.01, 
***p<0.001) was determined using an unpaired, two-tailed Student’s t-test. 
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RESULTS 
 
K-Ras activation in early embryonic NSCs leads to increased astrogliogenesis in vivo.  To define 
the impact of Ras hyperactivation on NSC function in vivo, we leveraged BLBP-Cre mice to target Cre 
recombinase expression (and Ras activation) to brain NSCs capable of multi-lineage differentiation 
beginning at E9.5 [19].  Expression of each individual activated Ras allele was accomplished using mice 
in which an oncogenic version was knocked into the endogenous Ras locus.  Specifically, these RasLSL 
(H-RasLSL-G12V, K-RasLSL-G12D, or N-RasLSL-G12D) mice contain a transcriptional stop element flanked by 
LoxP sites (Lox-Stop-Lox [LSL]) that prevents expression of the mutationally-activated Ras alleles in the 
absence of Cre expression.  Following Cre-mediated recombination, mutationally-activated Ras is then 
expressed from its endogenous promoter.  
At postnatal day 18 (PN18), there was a greater percentage of astrocytes in the brainstem of K-
RasBLBP, but not H-RasBLBP or N-RasBLBP, mice relative to littermate controls using the GFAP (1.8-fold) and 
S100β (1.2-fold) astrocyte markers (Figure 2.1A, 2.1B).  In contrast, there were no differences in APC+ 
oligodendrocytes (Figure 2.1C) or NeuN+ neurons (Figure 2.1D) or differences in brain or body weights 
across the three Ras genotypes relative to controls (Supplemental Figure S2.1). These data demonstrate 
that K-Ras, but not H-Ras or N-Ras, activation in NSCs leads to the generation of more astrocytes in vivo. 
 
Ras activation in later embryonic NSCs does not alter glial cell formation in vivo.  In order to 
determine if activating the individual Ras molecules in NSCs at a later brain developmental time point 
also increases gliogenesis in the brain, we intercrossed RasLSL mice with GFAP-Cre mice.  These mice 
express Cre recombinase in multipotent NSCs beginning at E14.5 [20, 21].  Upon Ras molecule 
activation in these NSCs, there was no difference in the percentage of brainstem GFAP+ astrocytes or 
APC+ oligodendrocytes in H-RasGFAP, K-RasGFAP, or N-RasGFAP mice at P18 (Figure 2.2A, 2.2B).  As with 
the RasBLBP mice, there were also no differences in the body or brain weights across the three Ras 
genotypes when compared to littermate controls (Supplemental Figure S2.2).  Taken together, these data 
demonstrate that K-Ras hyperactivation alone leads to increased astrocyte formation in vivo.  Moreover, 
this increase in astrocytes is dependent on K-Ras hyperactivation in NSCs at E9.5, but not at E14.5, 
suggesting that K-Ras* alters NSC function within a limited developmental time frame.   
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K-RasBLBP mice have more Sox2+ and Olig2+ progenitor cells in the developing embryonic and 
postnatal brain.  To determine how K-Ras hyperactivation at E9.5 alters the function of NSCs in the 
developing brain, we examined changes in two progenitor cell populations (Sox2+ NSCs, Olig2+ glial-
restricted progenitor cells) during brain development.  Specifically, we measured these progenitor cell 
populations at two developmental time points, shortly after K-RasBLBP activation (E12.5) and at birth 
(PN1).  At E12.5, the embryonic hindbrain represents the future location of the postnatal brainstem.  In 
this region, there was a 2-fold increase in Sox2+ NSCs per unit area (0.1mm2) observed in K-RasBLBP 
mice relative to littermate controls (Figure 2.3A, **p<0.01).  At PN1, there was no longer a difference in 
the percentage of Sox2+ NSCs in the brainstem of K-RasBLBP and littermate control mice (Figure 2.3B).  
However, at this time point there was a 1.9-fold increase in the percentage of Olig2+ glial-restricted 
progenitor cells (Figure 2.3C, ***p<0.001).  These data demonstrate that K-Ras hyperactivation in NSCs 
at an early developmental time point causes a brief expansion in the population of progenitor cells, which 
likely underlies the increase in astrocytes observed in the K-RasBLBP mouse brainstem at PN18.     
  
	   57 
DISCUSSION 
 
 The importance of RAS signaling during brain development is especially apparent in the context 
of the RASopathy family of neurodevelopmental disorders in which patients present with CNS defects 
such as neurocognitive deficits, learning difficulties, and behavioral abnormalities.  While all of the 
RASopathies result from aberrant RAS pathway hyperactivation, the gain-of-function mutations occurring 
in this pathway vary widely between the individual disorders.  Of particular interest to the current thesis, 
activating mutations do not occur uniformly within the RAS molecules.  For example, Costello Syndrome 
is caused exclusively by hyperactivating mutations in the H-RAS gene while hyperactivating mutations in 
K-RAS or N-RAS cause Noonan Syndrome in a small proportion (<5% each) of patients affected by this 
disorder.  This likely reflects the capacity of the individual RAS molecules to differentially alter cell growth 
and function during brain development.  To this end, it remains unclear how each individual RAS 
molecule contributes to the regulation of normal brain development.  Moreover, it is unknown if RAS 
pathway activation within different developmental time frames differentially disrupts normal brain 
development.  To address these questions, we expressed activated forms of H-Ras, K-Ras, and N-Ras in 
NSCs at both early and later stages of brain development.  This comparison allowed us to make several 
important observations about the Ras molecule-specific and time-specific consequences of Ras activation 
in the developing embryonic brain. 
First, we have demonstrated that K-Ras, but not H-Ras or N-Ras, activation in NSCs increases 
astrocyte formation in the postnatal brain (PN18).  Moreover, we have observed that this increase in K-
Ras*-mediated astrocyte formation occurs only when K-Ras is activated in NSCs early in brain 
development (E9.5).  When activated in NSCs later in brain development (E14.5), none of the three Ras 
molecules cause more astrocytes or oligodendrocytes to form in the postnatal brain.  These results 
suggest a time dependent role for activated K-Ras in specifying glial cell fate decisions.  Precedent for 
RAS-mediated regulation of cell fate decisions stems from several studies which examined the 
consequences of activation of Ras or its downstream Mek/Erk effectors on pro-neuronal and pro-glial fate 
decisions.  In favor of pro-neuronal Ras signaling, the Ras downstream effector protein Mek is required 
for the phosphorylation (activation) of the pro-neuronal C/EBP transcription factor in in vitro cortical NSCs 
[23].  This transcription factor directs expression of the neuron-specific gene Tα1 α-tubulin, causing these 
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NSCs to adopt a neuronal cell fate.  In vivo, expression of the Ras effector protein Erk2 is required for 
cortical NSCs to adopt a neuronal cell fate.  Conditional loss of the Erk2 gene in NSCs inhibits neuronal 
differentiation and instead results in increased astrocyte formation in the cortex, demonstrating that Erk2 
is required for neuronal differentiation in the cortex [24].  While these studies clearly identify a pro-
neurogenic role for Ras signaling in NSCs, other recent studies demonstrate a pro-gliogenic role for Ras 
signaling as well.  Introduction of activated H-Ras in cortical progenitor cells by in vivo electroporation 
inhibits cortical neurogenesis and increases progenitor cell proliferation and the adoption of glial cell fates 
[25].  Strikingly, the Ras downstream effector proteins Mek1/2 are critical for astrocyte fate specification in 
NSCs as loss of both genes in E11.5 NSCs in vivo causes the complete loss of astrocytes in the adult 
brain.  This loss of astrocytes can be rescued to wild-type levels by overexpression of Mek1 later in 
embryonic development (E15.5), indicating that Mek is both necessary and sufficient for astrocyte 
differentiation [26].  Although as a whole these studies suggest conflicting roles for Ras in either pro-
neurogenic or pro-glial differentiation programs, a recent study demonstrates that Ras can direct both cell 
fate decisions within the same progenitor cell population.  Upon expression of a constitutively activated 
form of Ras (RasG12V) in E12.5-E15.5 cortical progenitor cells in vivo, Ras inhibits expression of the pro-
neuronal transcription factor Ngn2 and induces expression of the traditionally pro-neuronal Mash1 
transcription factor in an Erk-dependent manner [27].  Subsequently, Mash1 is sufficient to specify both 
glial and neuronal cell fates in cortical progenitor cells in a Ras expression-dependent manner.  In cells 
expressing high levels of Ras, more Sox9+ proliferative glioblasts are formed, which differentiate into both 
astrocyte and oligodendrocyte precursor cells.  In contrast, moderate Ras expression induces some 
progenitor cells to become Dlx2+ GABAergic neurons.  Collectively, these studies define the capacity of 
Ras signaling to specify multiple cells fates during brain development.  Our data demonstrates that brain 
NSCs have a limited time frame in which they are sensitive to endogenously activated K-Ras signaling 
and suggests that K-Ras activation early in brain development might direct NSCs towards the glial 
(astrocyte) lineage rather than the neuronal lineage.  However, in vitro studies on the NSC cell-
autonomous consequences of Ras molecule activation (examined separately and discussed in Chapter 3) 
demonstrate that Ras does not alter NSC cell fate decisions in vitro.  This suggests that K-Ras activation 
at E9.5 is sufficient to alter NSC growth such that more astrocytes are formed by PN18. 
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 In support of this hypothesis, examination of Sox2+ and Olig2+ progenitor cells demonstrates that 
both cell populations are expanded at distinct time points during K-RasBLBP mouse brain development.  
The increase in Olig2+ restricted progenitor cells at an intermediate developmental time point (PN1) is 
significant as this transcription factor is found in astrocyte and oligodendrocyte progenitor cells and is 
required for their differentiation into mature glial cell types [28, 29].  It is important to note the similar fold-
change differences in these cell types between K-RasBLBP and littermate control mice at the different 
developmental time points.  At E12.5, Sox2+ NSCs are increased 2-fold in K-RasBLBP mice, Olig2+ 
progenitor cells at PN1 are increased 1.9-fold, and GFAP+ astrocytes at PN18 are increased 1.8-fold.  
This remarkably consistent increase in each cell type suggests a model in which K-Ras activation initiates 
a single, brief expansion of Sox2+ NSCs at E9.5.  Subsequently, these NSCs give rise to and similarly 
expand the proportion of Olig2+ restricted progenitor cells at PN1.  At this time point, there is no difference 
in the percentage of Sox2+ cells between K-RasBLBP and wild-type mice, further reinforcing the idea that 
the initial Sox2+ cells have all become Olig2+ cells by PN1.  Lastly, these glial restricted progenitor cells 
differentiate into an equal proportion of GFAP+ astrocytes in the postnatal brain.  
Taken together, this chapter defines a limited developmental window in which K-Ras activation 
alone impacts on the growth of NSCs in the developing brain.  While many studies have explored the 
activation of Ras downstream effector proteins such as Mek and Erk, this study is the first to not only 
compare the impact of endogenously-expressed activated forms of the three Ras molecules but also 
compares their activation at both early and late developmental time points within the same progenitor cell 
population.  Further studies are required to examine whether K-Ras activation alters NSC function in a 
cell-autonomous manner and the signaling mechanism by which Ras might alter NSC function.  These 
studies and their experimental outcomes are discussed in detail in Chapter 3. 
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Figure 2.1. K-Ras activation in E9.5 NSCs leads to increased gliogenesis in vivo.  At PN18,            
K-RasBLBP, but not H-RasBLBP or N-RasBLBP, mice harbor an increased percentage of astrocytes in the 
brainstem quantified using the (A) GFAP (1.8-fold, **p<0.01) and (B) S100β (1.2-fold) astrocyte markers. 
Representative images appear on the right (20x, scale bar=50µm).  There were no changes in the 
percentages of (C) APC+ oligodendrocytes or (D) NeuN+ neurons in the three RasBLBP genotypes relative 
to littermate controls. Error bars represent the standard errors of the mean. 
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Figure 2.2.  Ras activation in E14.5 NSCs does not alter glial cell formation in vivo.  At PN18,        
H-RasGFAP, K-RasGFAP, and N-RasGFAP mice do not harbor any differences in the percentage of brainstem 
(A) GFAP+ astrocytes and (B) APC+ oligodendrocytes relative to littermate controls. Error bars represent 
the standard errors of the mean.  
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Figure 2.3.  K-RasBLBP mice have more neuroglial progenitors during early brain development.     
(A) At embryonic day 12.5 (E12.5), K-RasBLBP mice have 2–fold more Sox2+ NSCs per 0.1mm2 in the 
developing hindbrain, the future site of the brainstem pons, compared to littermate controls (**p<0.01).  
Representative images appear to the right with Sox2+ cells in green and the dashed line demarking the 
ventricular surface (20x, scale bar=50µm).  (B) At postnatal day 1 (PN1), there is no difference in the 
percentage of Sox2+ NSCs in the brainstem, however, (C) K-RasBLBP mice have 1.9–fold more Olig2+ glial 
progenitor cells compared to littermate controls (***p<0.001).  Representative images appear to the right 
of their respective graphs with arrowheads identifying Sox2+ or Olig2+ nuclei (red), respectively.  DAPI 
(blue) marks total cells (20x, scale bar=50µm).         
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Supplemental Figure S2.1. Targeting strategy for the H-RasLSL-G12V mouse. Schematic representation 
of H-RasLSL-G12V mice at the endogenous H-Ras locus in murine embryonic stem cells.  A transcriptional 
stop site flanked by LoxP sites (lox-stop-lox [LSL]) was inserted upstream of a G12V activating point 
mutation (*) in the first coding exon of H-Ras. 
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Supplemental Figure S2.2. Imaging the postnatal brainstem pons. Six - 0.1mm2 images were 
acquired per postnatal brain within the reticular nucleus (dashed outline) of the brainstem. 
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Supplemental Figure S2.3. Ras activation in BLBP-Cre-expressing NSCs does not alter body or 
brain weight. Ras activation does not significantly change (A) body or (B) brain weight of H-RasBLBP, K-
RasBLBP, or N-RasBLBP mice relative to littermate controls. 
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Supplemental Figure S2.4. Ras activation in GFAP-Cre-expressing NSCs does not alter body or 
brain weight. Ras activation does not significantly change (A) body or (B) brain weight of H-RasGFAP, K-
RasGFAP, or N-RasGFAP mice relative to littermate controls. 
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Table S2.1. Antibodies for immunohistochemistry (IHC) and immunofluorescence (IF). 
Antibody Species  Application Antigen Retrieval Source Dilution 
APC mouse IHC 10mM Sodium Citrate Millipore,  Billerica, MA 1:50 
GFAP mouse IHC 10mM Sodium Citrate Millipore 1:500 
NeuN mouse IHC 10mM Sodium Citrate Millipore 1:250 
Olig2 rabbit IF --- Millipore  1:500 
S100β rabbit IHC 10mM sodium citrate + 1mM EDTA 
Sigma-Aldrich,  
St. Louis, MO 1:1,000 
Sox2 rabbit IF --- Millipore 1:1,000 
Sox2 mouse IF --- Abcam 1:1,000 
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CHAPTER 3  
 
RAS ACTIVATION IN NEURAL STEM CELLS IN VITRO 
 
  
	   72 
INTRODUCTION 
 
Neural stem cells (NSCs) represent a self-renewing population of cells found in the neurogenic 
regions of the embryonic and adult brain [1, 2]. In addition to forming new NSCs (symmetric division, self-
renewal, and proliferation), these stem cells can also give rise to all the major cell types in the brain, 
including neurons, oligodendrocytes, and astrocytes, through multi-lineage differentiation (asymmetric 
division) [3-6]. Each of these cell fate decisions (self-renewal versus differentiation) requires the activation 
of signaling pathways and transcriptional programs [3, 7-11]. In this regard, previous studies have 
identified numerous potential regulatory mechanisms involving p53, bmi1, sonic hedgehog (SHH), Notch, 
p27, REST/NSRF, epidermal growth factor receptor, and others [12-23]. While many of these signaling 
molecules may be responsible for NSC growth and differentiation, it is not clear which of the many 
effectors are important for the pathogenesis of diseases characterized by abnormal brain NSC function.  
A number of neurodevelopmental disorders, including neurofibromatosis type 1 (NF1), Costello 
syndrome, and Noonan syndrome, are caused by germline mutations in genes that lead to 
hyperactivation of the Ras proto-oncogene [24-27].  Small GTPase proteins, like Ras, act as molecular 
switches by alternating between active, GTP-bound and inactive, GDP-bound states [28]. In each of the 
above neurogenetic conditions, there is more Ras in the active GTP-bound form, leading to increased 
Ras pathway signaling. The critical importance of Ras to brain development is underscored by mouse 
genetic knockout studies, in which de-regulated Ras signaling is associated with brain developmental 
defects or embryonic lethality [29-33]. 
Ras exists as three separate molecules (H-Ras, K-Ras, and N-Ras) in the mammalian brain. 
Despite 85% similarity in amino acid sequence across all of the Ras molecules, Ras molecule-specific 
function is dictated by unique hypervariable regions (HVRs) encoded by distinct C-terminal 25-amino acid 
sequences. While the HVR of all Ras molecules contains a CAAX-box motif which is isoprenylated to 
allow for proper targeting of Ras to the plasma membrane (PM) [34], differential palmitoylation directs 
their trafficking to the PM via the Golgi (H-Ras, N-Ras) or another, unknown mechanism (K-Ras) [35, 36]. 
This differential processing directs the different Ras molecules to distinct domains within the PM [37], and 
is thought to underlie their differential capacities to signal to downstream effector proteins in different 
cellular contexts [34, 38, 39].  
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Based on these potential differences, we hypothesized that H-Ras, K-Ras, and N-Ras may 
differentially regulate brain NSC growth and differentiation. Using in vitro approaches, we demonstrate 
that hyperactivation of K-Ras, but not H-Ras or N-Ras, increases brain NSC proliferation without altering 
multi-lineage differentiation. Moreover, we report that K-Ras controls brain NSC growth in a Raf-
dependent, but Mek-independent manner, through binding and inhibition of retinoblastoma protein (Rb) 
function. Collectively, these results demonstrate that the Ras molecules have distinct biological effects on 
brain NSC function. 
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MATERIALS AND METHODS 
 
Mice. NSCs for in vitro culture were collected from the brainstem of mice containing Lox-Stop-Lox (LSL)-
H-RasG12V (Supplemental Figure S2.1; generated by Dr. Kevin Haigis), LSL-K-RasG12D [40], or LSL-N-
RasG12D [41] constructs knocked into the respective Ras locus.  All mice were maintained on a C57Bl/6 
background in accordance with approved animal studies protocols at Washington University.  
 
Neural Stem Cell (NSC) Culture. NSCs were generated from brainstems of PN1 mice as previously 
reported [42]. Briefly, dissociated brainstem tissue was cultured for five days in NSC-selective media 
supplemented with 1% N2 (Life Technologies, Grand Island NY), 2% B27 (Life Technologies), 20ng/mL 
fibroblast growth factor (FGF) (Sigma-Aldrich, St. Louis, MO) and 20ng/mL epidermal growth factor (EGF) 
(R&D Systems, Minneapolis, MN) in ultra-low attachment dishes (Corning, Corning, NY). The expression 
of activated H-Ras, K-Ras, or N-Ras molecules was induced in NSCs following Ad5-Cre (University of 
Iowa Gene Transfer Vector Core, Iowa City, IA) infection. Ad5-LacZ-infected NSCs were used as 
controls. Ras activity was quantified using a Raf1-Ras binding domain (RBD) affinity chromatography 
assay kit (Millipore, Billerica, MA). NSC growth was assessed by direct cell counting following the seeding 
of 5,000 NSCs (in triplicate) in 24-well ultra-low attachment dishes containing NSC media (Corning). Cells 
were typsinized and counted using a hemocytometer after five days in culture. For all NSC growth and 
differentiation assays, experiments were performed on NSCs maintained in culture for fewer than three 
passages.   
 
Immunofluorescence. Neurospheres were collected after five days in culture, washed twice in PBS, and 
fixed for 30 minutes in 4% paraformaldehyde.  Following fixation, neurospheres were dehydrated in 30% 
sucrose for at least 24 hours prior to embedding in OCT mounting media (Sakura Finetek, Torrance, CA) 
and freezing at -80°C. All neurospheres were sectioned on a Reichert-Jung Cryocut 1800 (Reichert 
Technologies, Depew, NY) cryostat into 10µm-thick sections. Primary antibodies (Supplemental Table 
S3.1) were applied overnight at 4°C followed by incubation with species-appropriate AlexaFluor® 488 or 
568 secondary antibodies (Life Technologies) and counterstained with DAPI.  At least eight neurospheres 
of similar diameter and cell number were imaged per sample using a Nikon Eclipse TE300 inverted 
	   75 
fluorescent microscope with a Photometrics CoolSnap EZ camera (Photometrics, Tucson, AZ) and 
compared to LacZ-infected control cells.  
  
Immunocytochemistry. Differentiation was assessed using methods previously published [17].  Briefly, 
150,000 NSCs were plated in triplicate and allowed to adhere onto 24-well plates coated with 50µg/mL 
poly-D-lysine (Sigma-Aldrich) and 10µg/mL fibronectin (Life Technologies) in NSC media supplemented 
with 1% N2, 2% B27, and 1% fetal bovine serum.  After six days in culture, adherent cells were fixed for 
15 minutes in 4% paraformaldehyde and stained using primary antibodies listed in Supplemental Table 
S1.  Cells were incubated with species-appropriate AlexaFluor® 488 or 568 secondary antibodies (Life 
Technologies) and counterstained with DAPI.  For the EdU studies, 20µM 5-ethynyl-2'-deoxyuridine (EdU; 
Life Technologies) was added to the culture media 3 hours prior to fixation.  EdU was detected using the 
Click-IT® EdU Assay Kit (Life Technologies) according to manufacturer’s protocol prior to 
immunocytochemistry staining.  Each experiment was repeated a minimum of three times using NSCs 
harvested from three independently-generated litters. 
 
Immunoprecipitation. Raf-1 immunoprecipitation was performed on whole cell lysates in a binding buffer 
containing 20mM HEPES (pH 7.9), 40mM KCl, 1mM MgCl2, 0.1mM EGTA, 0.1mM EDTA, 0.1mM 
dithiothreitol, 0.1 NaF, 0.1mM Na3VO4, 0.5% IGEPAL, and 3mg/mL BSA. Total protein (500µg) in 400µl of 
binding buffer was pre-cleared with 30µl agarose protein G beads (Cell Signaling) for 2 hours at 4°C on a 
rotor. After removing the beads, lysates were incubated with Raf-1 monoclonal antibodies (Millipore) 
overnight at 4°C on a rotor. Agarose beads were added to these lysates, and incubated for 2 hours on a 
rotor at 4°C. The beads were washed three times in 500µl binding buffer, boiled in 20µl 4x Laemmli 
buffer, and separated on an 8% polyacrylamide gel for Western blotting.  Raf-1 pull-down was confirmed 
by blotting with a different Raf-1 antibody (Cell Signaling).  Each experiment was repeated a minimum of 
three times using NSCs harvested from three independently-generated litters. 
 
Flow Cytometry Analysis. Neurospheres were trypsinized and then fixed overnight in 50% ethanol in 
PBS containing 0.02% IGEPAL (Sigma-Aldrich). Following fixation, cells were washed three times in PBS 
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prior to trypsinization ((0.003% trypsin type-II (Sigma-Aldrich) in DNA analysis solution (0.1% IGEPAL, 
0.05% spermine tetrahydrochloride (Sigma-Aldrich) in 3.9mM sodium citrate buffer)) for 10 minutes at 
room temperature. Cells were subsequently incubated for 10 minutes at room temperature in 
trypsinization inhibitor solution (0.05% trypsin inhibitor type-O (Sigma-Aldrich), 0.001% RNase A (Sigma-
Aldrich) in DNA analysis solution) prior to staining (0.02% propidium iodide (Sigma-Aldrich), 0.015% 
spermine tetrachloride in DNA analysis solution) for 10 minutes at room temperature.  
Apoptosis was measured using trypsinized neurospheres. Live cells were stained for annexin V 
and propidium iodide using an Annexin V-FITC Apoptosis Detection Kit (Abcam, Cambridge, MA) 
according to manufacturer’s protocol. All samples were quantitated on a Beckton Dickinson FACScan 
machine (Beckton Dickinson, Franklin Lakes, NJ) using FlowJo acquisition and analysis software 
(TreeStar Inc., Ashland, OR). 
 
Western Blotting. Western blotting was performed as previously described [43] with appropriate primary 
antibodies (Supplemental Table S3.2). Detection was achieved using species-appropriate HRP-linked 
secondary antibodies (Cell Signaling, Danvers, MA) and enhanced chemiluminescence imaging (BioRad) 
using the ChemiDoc-It Imaging System (UVP, Upland, CA).   
 
Pharmacological Inhibition Studies. Optimal drug concentrations for all inhibitor studies were 
experimentally determined by dose escalation (data not shown). Following optimization, NSCs were 
treated with either 6.5µM GGTI-286 (Millipore), 200nM AZ628 (Selleck Chemicals, Houston TX), 2nM 
PD0325901 (Selleck Chemicals), 50nM AZD0530 (Selleck Chemicals), 20µM SB203580 (Selleck 
Chemicals), or 5 µM RRD-251 (Sigma-Aldrich) for five days in culture. Control cells were treated with 
DMSO.    
 
Data Analysis. Tissue and cell staining images were quantitated using ImageJ image analysis software 
(U.S. National Institutes of Health). The Grubbs outlier test was used to determine statistical outliers and 
statistical significance (*p<0.05, **p<0.01, ***p<0.001) was determined using an unpaired, two-tailed 
Student’s t-test and GraphPad Prism 5 software (GraphPad Software, La Jolla CA).  
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RESULTS 
 
K-Ras activation does not alter NSC astrocyte differentiation. Based on the observed increase in 
astrogliogenesis in vivo described in Chapter 2, we employed neurosphere cultures generated from the 
brainstems of PN1 pups infected with adenovirus expressing either LacZ (control cells, CTL) or Cre 
recombinase (activated H-Ras, K-Ras, or N-Ras, denoted H-Ras*, K-Ras*, and N-Ras*, respectively) to 
determine whether K-Ras activation results in a change in brain NSC astrocyte differentiation. Active Ras-
GTP pull-down by Raf1-RBD affinity chromatography confirmed that each of the Ras molecules was 
comparably activated following Ad5-Cre infection (Figure 3.1A).  Upon in vitro differentiation of these 
NSCs over six days in adherent culture, only K-Ras*-expressing NSCs exhibited increased numbers of 
GFAP+ astrocytes (1.8-fold) relative to controls (Figure 3.1B). Importantly, K-Ras*-expressing NSC 
cultures also showed an increase in the total number of DAPI+ cells (1.8-fold) compared to control cells 
(Figure 3.1C).  The increase in GFAP+ cells proportional to total DAPI+ cells resulted in no change in the 
percentage of GFAP+ cells compared to controls (Figure 3.1D), indicating that K-Ras activation does not 
directly change NSC astrocyte differentiation. 
Since we observed no change in astrocyte differentiation, we next sought to determine whether 
the increase in astrocyte numbers following K-Ras* expression reflected an increase in the NSC pool 
during differentiation. This was assayed by EdU incorporation in the six-day differentiation assay, 
observing differentiating cells at both early (one day post-plating) and late (five days post-plating) time 
points in the assay (Figure 3.2A).  In addition to EdU incorporation, markers for NSCs (Sox2) and 
astrocytes (GFAP) were used to measure changes in both populations throughout the differentiation 
assay. After one day in culture, K-Ras*-expressing cells were proliferating 7.4-fold more than their control 
counterparts (Figure 3.2B). These proliferating cells were exclusively Sox2+ NSCs, and not GFAP+ 
astrocytes (Figure 3.2C). At this time point, there was no difference in the percentage of control or K-Ras* 
cells positive for Sox2, however, a significantly smaller percentage of K-Ras*-expressing cells were 
GFAP+ compared to control cells (Figure 3.2D).  After five days in culture, the K-Ras*-expressing cells 
were still proliferating 2.2-fold more than controls (Figure 3.2E), however, there was no difference in 
proliferating NSCs or astrocytes (Figure 3.2F).  Importantly, a significantly higher percentage (1.6-fold) of 
K-Ras*-expressing cells were Sox2+ NSCs relative to control cells, while there was no difference in the 
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percentage of GFAP+ astrocytes in either K-Ras* or control cell populations (Figure 3.2G). Taken 
together, these data indicate that K-Ras activation increases the NSC pool, rather than driving NSCs 
towards astrocyte differentiation.  
 
K-Ras activation increases NSC proliferation in vitro. To determine whether the individual Ras* 
molecules differentially increase NSC growth in vitro, we directly counted NSCs after five days in culture. 
Similar to the previous in vitro data, K-Ras*-, but not H-Ras*- or N-Ras*-, expressing NSCs grew 2.3-fold 
more than controls (Figure 3.3A). Immunofluorescence staining of sectioned neurospheres after five days 
in neurosphere culture confirmed that K-Ras*-, but not H-Ras*- or N-Ras*-, expressing neurospheres 
have a 1.6-fold increase in the percentage of Ki67+ proliferating cells (Figure 3.3B). To determine whether 
increased K-Ras* NSC growth results from increased proliferation or decreased cell death, we utilized 
flow cytometry to analyze both potential etiologies in the same NSC samples. Using propidium iodide to 
quantitatively stain cellular DNA content, fewer K-Ras*-expressing NSCs were found in the pre-cycling 
G0/G1 phase (-4.6%) of the cell cycle relative to controls, while more K-Ras*-expressing NSCs were found 
in S phase (+3.6%) and G2/M phase (+2.6%) (Figure 3.3C, 3.3D). Using annexinV staining to identify cells 
undergoing programmed cell death (apoptosis), we found no difference between live and apoptotic K-
Ras*-expressing and control NSCs (Figure 3.3E, 3.3F). These data demonstrate that K-Ras activation 
enhances NSC growth by increasing proliferation rather than by decreasing apoptosis. Together, these in 
vitro assays are consistent with a model that K-Ras hyperactivation promotes an approximately 1.7-fold 
increase in NSC proliferation, expanding the NSC pool, and resulting in a proportional increase (1.8-fold) 
in astrocyte formation upon differentiation (Figure 3.3G).    
 
K-Ras increases NSC proliferation in a Raf-dependent, but Mek-independent, manner. To define the 
signaling pathway responsible for activated K-Ras control of NSC proliferation, we performed a series of 
pharmacological inhibitor studies. First, we confirmed that K-Ras activation is required for K-Ras*-induced 
NSC hyperproliferation using the GGTI-286 geranylgeranyltransferase inhibitor. Following GGTI-286 
(6.5µM) treatment, the hyperproliferation of K-Ras* NSCs was reduced to that of controls, as measured 
by direct cell counting (Figure 3.4A). Second, following inhibition with the pan-Raf inhibitor AZ628 
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(200nM), K-Ras*-induced NSC hyperproliferation was also attenuated to that of control cells (Figure 
3.4B). Consistent with Ras- and Raf-mediated hyperactivation, increased Erk activation was observed in 
K-Ras*-expressing NSCs (Figure 3.4C). Third, to determine whether Raf/Mek signaling was responsible 
for K-Ras*-induced NSC hyperproliferation, K-Ras*-expressing NSCs were treated with the PD0325901 
(PD901; 2nM) Mek inhibitor. Despite reduction of Erk activity to control cell levels, PD901 treatment did 
not reduce K-Ras*-mediated NSC hyperactivation to control cell levels (Figure 3.4D).  
This unexpected result prompted an examination of potential Raf effector proteins. While we 
observed no change in Akt, Jnk, PKC-γ, PKC-ζ, Ran, β-catenin, and Yap activity, Src and p38MAPK were 
hyperactivated (increased SrcY416 and p38MAPKT180/Y182 phosphorylation, respectively) in K-Ras*-
expressing NSCs compared to controls (Supplemental Figure S3.1A, S3.1B). However, pharmacologic 
inhibition of Src (50nM AZD0530) or p38MAPK (20µM SB203580) activity did not reduce K-Ras*-induced 
NSC hyperproliferation (Supplemental Figure S3.1C, S3.1D). Similarly, neither GGTI-286 (Ras inhibitor) 
nor AZ628 (Raf inhibitor) treatment reduced Src and p38MAPK hyperactivation (Supplemental Figure 
S3.1E). Collectively, these data demonstrate that K-Ras* expression increases NSC proliferation in a Raf-
dependent, but Mek-, Src-, and p38MAPK-independent, manner.   
 
Raf-1 inhibition of Rb is responsible for K-Ras-induced NSC proliferation.  To determine how K-
Ras* expression regulates NSC proliferation, we focused on potential Raf-dependent mechanisms. 
Previous studies have shown that Raf-1 (c-Raf) directly binds the retinoblastoma tumor suppressor 
protein (Rb) to relieve Rb-mediated suppression of cell cycle progression [44]. We found that endogenous 
Rb bound to Raf-1 in K-Ras*-expressing NSCs as assessed by Raf-1 immunoprecipitation (Figure 3.5A). 
Based on these findings, we employed a small peptide inhibitor, RRD-251, previously shown to disrupt 
the Raf-1/Rb interaction [45, 46], to demonstrate that this interaction is required for K-Ras*-mediated NSC 
hyperproliferation. Treatment of K-Ras*-expressing NSCs with RRD-251 (5 µM) reduced K-Ras*-induced 
NSC hyperproliferation to control levels (Figure 3.5B). Together, these data establish a new model for K-
Ras* regulation of NSC proliferation, in which K-Ras-GTP activation of Raf leads to Rb binding and 
inhibition, and leads to increased G0/G1-S transition and proliferation (Figure 3.5C). 
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DISCUSSION 
 
Despite the central role of Ras in regulating embryonic development, the three Ras molecules do 
not equally impact on this process. For example, bi-allelic K-Ras deletion in mice results in lethality 
between 12 and 14 days of gestation, resulting from brainstem defects, hematopoietic abnormalities, and 
organ failure [29, 30]. In striking contrast, H-Ras or N-Ras deletion, either separately or in combination, 
does not interfere with normal embryonic development and results in healthy adult mice, indistinguishable 
from wild-type littermates [47, 48]. These differential effects are further highlighted by observations made 
in human neurogenetic disorders characterized by germline mutations in genes whose protein products 
regulate Ras activity (collectively termed “RASopathies”). In these RASopathies, which include Costello 
syndrome, Noonan syndrome, and neurofibromatosis type 1 (NF1), Ras activation is abnormally elevated. 
However, the causative RAS mutations are different: In Costello syndrome, H-RAS mutations [26] have 
been reported, whereas Noonan syndrome patients harbor K-RAS mutations [27], each with varying 
neurocognitive delays and learning disabilities. Similarly, in NF1, loss of Nf1 gene expression in mouse 
brain NSCs from the third ventricle, lateral ventricle, and brainstem all lead to Ras hyperactivation [17, 42, 
49]. While it is not known which Ras molecules are hyperactivated in these Nf1-deficient NSCs, only K-
Ras activity is increased following Nf1 loss in astrocytes [50]. This differential Ras activation is 
underscored by the finding of oncogenic K-RAS, but not H-RAS or N-RAS, mutations in pediatric brain 
tumors [51, 52], and prompted us to investigate the impact of each individual Ras molecule on brain NSC 
function. In this chapter, we make several important observations. 
Herein, we demonstrate that activated K-Ras, but not H-Ras or N-Ras, increases the proliferation 
of brain NSCs. While no prior studies have systematically compared the three Ras molecules in the brain, 
previous work in other tissue types revealed divergent functions of these Ras molecules. In neural crest-
derived hematopoietic cells, activated N-Ras is the primary regulator of cell self-renewal, proliferation, 
and cell fate decisions [53-56], whereas activated K-Ras primarily drives cell growth in tissues arising 
from the endoderm (lungs, colon) [40, 57]. Similarly, in endoderm-derived stem cells, overexpression of 
active H-RasG12V promotes cell differentiation and suppresses cell growth, in contrast to K-RasG12V 
overexpression that conversely promotes stem cell proliferation and inhibits cell differentiation [58]. 
Moreover, K-RasG12D expression increases the proliferation of an intestinal stem cell population, whereas 
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N-RasG12D expression increases the resistance of these cells to apoptosis without changing cell 
proliferation [41]. Lastly, K-RasG12D expression has also been reported to cause bronchioalveolar stem 
cell hyperproliferation in the lung [57]. Taken together, these studies identify K-Ras* as a potent driver of 
progenitor cell proliferation, which is consistent with our finding that only K-Ras activation promotes brain 
NSC proliferation.  
Given the high level of sequence similarity between the three Ras molecules and their capacity to 
signal to a similar subset of downstream effector proteins, it seems counterintuitive that these molecules 
should have such divergent functions. However, these differences are conferred by unique 25-amino 
acid, C-terminal HVRs. During post-translational processing, the Ras molecules are first prenylated by 
farnesyltransferase, which allows for trafficking to the endoplasmic reticulum [59, 60]. After this step, Ras 
molecule post-translational processing diverges: K-Ras becomes more highly methylated than its H-Ras 
and N-Ras counterparts [35]. H-Ras and N-Ras are then palmitoylated and trafficked to the plasma 
membrane through the Golgi apparatus while methylated K-Ras is trafficked to the plasma membrane 
independent of the Golgi [36, 61]. While the exact mechanism of K-Ras trafficking is unknown, its 
transport is dependent on a polybasic, lysine-rich portion of the K-Ras HVR not found within the HVRs of 
H-Ras or N-Ras [62]. Following its localization at the plasma membrane, each Ras molecule occupies a 
different microdomain: N-Ras is found in lipid raft domains, while K-Ras localizes to non-lipid raft portions 
of the membrane [37, 63]. H-Ras occupies lipid raft domains when inactive, but translocates to non-lipid 
raft membrane upon activation (in areas distinct from those occupied by K-Ras) [37, 64].  In addition, H-
Ras and N-Ras are also capable of signaling to downstream effectors from the Golgi, a capability not 
shared by K-Ras [65, 66]. Collectively, the divergent processing and localization of the Ras molecules 
likely account for their capacities to signal to different subsets of downstream proteins to generate 
different biological outcomes [38, 39]. 
Ras/Raf signal transduction most commonly operates through Raf activation of Mek1/2 [67-69]. In 
striking contrast to this canonical signaling mechanism, we demonstrate that K-Ras* regulates brain NSC 
proliferation in a Raf-dependent manner that operates independent of Mek. Precedent for Mek-
independent Ras/Raf growth control derives from several studies performed in numerous different cell 
types.  First, Raf-1 overexpression has been shown to increase cell survival by inhibiting ASK-1 function 
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in the presence of the Mek pharmacological inhibitors PD98059 and U0126 [70]. Second, K-Ras*-
expressing DLD-1 cells continue to proliferate despite treatment with the Mek inhibitor CI-1040. 
Proliferation of these cells was only inhibited in the presence of the Raf inhibitor AZ628 [41]. Third, protein 
binding discovery studies have revealed several other potential Raf binding partners, including the 14-3-
3-zeta protein, which modulates Raf signaling during cell stress through its association with keratin 8/18 
[71, 72]. Fourth, both B-Raf and Raf-1 associate with PKC-theta to inactivate the pro-apoptotic Bcl-2 
family protein BAD and increase cell survival [73]. While these studies collectively identify a role for Raf in 
cell growth, we found that K-Ras-dependent brain NSC hyperproliferation depends on the productive 
interaction between Raf-1 and the retinoblastoma (Rb) cell cycle regulator [44].  
The Rb tumor suppressor protein regulates G0/G1 to S phase cell cycle progression. In quiescent 
cells, Rb prevents cell cycle progression by inhibiting the expression of the E2F transcription factors to 
prevent DNA synthesis. Upon growth factor stimulation, this inhibition is relieved, allowing cells to 
progress through the cell cycle. Using genetic and biochemical techniques to alter Ras expression in the 
presence or absence of Rb expression, early work established a hierarchy for Ras/Rb/cell cycle 
regulation, whereby Ras inhibition of Rb function led to increased cell cycle progression (proliferation) [74, 
75]. The mechanism underlying this Ras/Rb connection was identified when direct binding between Raf-1 
and Rb was revealed [44]. Interrupting this interaction with the RRD-251 small peptide has been shown to 
block tumor cell growth in numerous model systems [44-46, 76-78]. Consistent with these findings, we 
demonstrate that K-Ras*-induced brain NSC hyperproliferation is dependent on Raf/Rb binding and 
inhibition of Rb function.     
Taken together, using a novel collection of conditional Ras GEM strains and derivative brain 
NSCs, we establish differential effects of the three Ras molecules on brain NSC proliferation. Moreover, 
the elucidation of a non-conventional mechanism underlying Ras/Raf-mediated brain NSC growth control 
suggests additional determinants relevant to the study of diseases characterized by de-regulated RAS 
function. Future studies characterizing differences in Ras molecule function in disease-pertinent models 
will be critical to further defining and ultimately treating these disorders. 
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Figure 3.1. K-Ras activation does not affect NSC multi-lineage differentiation. (A) Ras activation 
(Ras-GTP) is increased in all three Ras* NSC populations after Cre expression. (B) K-Ras*-, but not      
H-Ras*- or N-Ras*-, expressing NSCs have a greater number of GFAP+ astrocytes compared to controls 
(1.8-fold, ***p<0.001). Graphs of representative experiments are shown with representative images 
included (GFAP+ (green) and DAPI+ (blue), 20x, scale bar=50µm). (C) K-Ras*, but not H-Ras* or N-Ras*, 
-expressing NSCs also give rise to more total DAPI+ cells compared to control cells (1.8-fold, ***p<0.001). 
(D) K-Ras*-, H-Ras*-, and N-Ras*-expressing NSCs do not have significantly different percentages of 
GFAP+ astrocytes compared to controls. Error bars represent the standard errors of the mean. 
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Figure 3.2. K-Ras activation increases NSC proliferation during differentiation. (A) EdU labeling at 
day 1 and day 5 post-plating was employed to determine whether Sox2+ NSCs or GFAP+ astrocytes 
proliferate during NSC differentiation. (B) K-Ras*-expressing cells proliferate 7.2-fold more than control 
cells at day 1 (***p<0.001). (C) These EdU+ proliferating cells are exclusively Sox2+ NSCs, and not 
GFAP+ astrocytes. (D) At day 1, there is no significant difference in the percentage of Sox2+ NSCs 
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between K-Ras* and control cell populations, however, there is a significant decrease in GFAP+ 
astrocytes in K-Ras*-expressing cells relative to controls. (E) At day 5, K-Ras*-expressing cells proliferate 
2.2-fold more than controls (*p<0.05). (F) There was no difference between proliferating NSCs (Sox2+) 
and astrocytes (GFAP+) in K-Ras*-expressing versus control cells.  (G) At day 5, K-Ras*-expressing cells 
have a 1.6-fold increase in the percentage of Sox2+ NSCs compared to control cells, while there is no 
difference in the percentage of GFAP+ astrocytes between the two cell populations (**p<0.01).  All graphs 
are representative experiments; error bars represent the standard errors of the mean.  Representative 
images for (D) and (G) appear below their respective graphs (20x, scale bar=50µm).  Arrowheads mark 
representative EdU+/Lineage+ double-positive cells, arrows mark cells positive for GFAP alone, and 
asterisks (*) mark cells positive for EdU alone. 
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Figure 3.3. K-Ras activation increases NSC proliferation in vitro.  (A) K-Ras*-, but not H-Ras*- or N-
Ras*-, expressing NSCs have increased growth as measured by direct cell counting (2.3-fold, 
***p<0.001). (B) K-Ras*-, but not H-Ras*- or N-Ras*-, expressing neurospheres have an increased 
percentage of Ki67+ cells relative to controls (1.6-fold, ***p<0.001, 20x, scale bar=50µm). Graphs include 
representative experiments. (C, D) Flow cytometry of fixed propidium iodide (PI)-stained NSCs 
demonstrates an increased percentage of K-Ras*-expressing NSCs in S phase (+3.6%) and G2/M phase 
(+2.6%) than in G0/G1 phase of the cell cycle (-4.6%) compared to control cells (*p<0.05. ***p<0.001).  (C) 
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Shows one representative experiment, while (D) includes the data from all four experiments. (E, F) Flow 
cytometry of live NSCs shows no difference in the percentage of live (propidium iodide-, annexin V-) 
versus apoptotic (annexin V+) cells. (E) Shows one representative experiment, while (F) includes the data 
from all four experiments. (G) Incorporating the data from all in vitro assays suggests a model in which K-
Ras hyperactivation promotes NSC proliferation (1.7-fold) which leads to a proportional increase in 
astrocyte formation (1.8-fold). 
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Figure 3.4. K-Ras regulates NSC proliferation in a Raf-dependent, but Mek-independent, manner. 
K-Ras*-induced NSC hyperproliferation is reduced to control levels following pharmacological inhibition of 
(A) Ras (GGTI-286, 6.5µM) (*p<0.05) and (B) Raf (AZ628, 200nM) (**p<0.01). (C) The downstream Ras 
effector, Erk1/2 (p-ErkT202/Y204) is hyperactivated in K-Ras*-expressing NSCs relative to controls. (D) K-
Ras*-induced NSC hyperproliferation following pharmacological inhibition with the Mek inhibitor 
PD0325901 is not reduced back to control cell levels (PD901, 2nM).   
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Figure 3.5. K-Ras regulates NSC proliferation in a Raf- and Rb-dependent manner. (A) Raf-1 
immunoprecipitation reveals that Rb binds to Raf-1 in K-Ras*-expressing NSCs. (B) The small molecule 
inhibitor RRD-251 reduces K-Ras*-induced NSC hyperproliferation to control levels, as measured by 
direct cell counting (*p<0.05). (C) Proposed model for K-Ras*-mediated regulation of NSC proliferation. 
Active K-Ras-GTP activates Raf by binding to the Ras-binding domain (RBD). This leads to subsequent 
Rb binding to and inhibition of Rb activity, culminating in increased cell cycle progression (proliferation). 
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Supplemental Figure S3.1. K-Ras*-, but not H-Ras*- or N-Ras*-, expressing NSCs exhibit increased 
Erk, p38MAPK, and Src activation. (A) K-Ras activation in NSCs activates both canonical and non-
canonical downstream effector proteins. (B) p-ErkT202/Y204, p-p38MAPKT180/Y182, and p-SrcY416 expression 
are increased in K-Ras*, but not H-Ras* or N-Ras*, NSCs. However, pharmacologic inhibition of (C) Src 
(AZD0530, 50nM) and (D) p38MAPK (SB203580, 20µM) activity did not inhibit K-Ras*-mediated NSC 
hyperproliferation. (E) Western blotting of DMSO-, GGTI-286-, and AZ628-treated K-Ras*-expressing 
NSCs reveal no reduction in p-SrcY416 and p-p38MAPKT180/Y182 hyperactivation in K-Ras*-expressing 
NSCs. 
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Table S3.1. Antibodies for immunocytochemistry (ICC), immunofluorescence (IF), and 
immunoprecipitation (IP). 
 
Antibody Species  Application Source Dilution 
GFAP mouse ICC Millipore, Billerica, MA 1:1,000 
Ki67 rabbit ICC Abcam, Cambridge, MA 1:1,000 
Ki67 mouse IF BD Biosciences, San Jose, CA 1:500 
O4 mouse ICC Millipore 1:1,000 
Raf-1 rabbit IP Millipore 1:50 
Sox2 rabbit ICC Millipore 1:1,000 
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Table S3.2. Antibodies for western blotting. 
  
Antibody Protein Size Species Source Dilution 
Akt 60 kDa rabbit Cell Signaling, Danvers, MA 1:5,000 
p-AktT308 60 kDa rabbit Cell Signaling 1:500 
p-AktS473 60 kDa rabbit Cell Signaling 1:5,000 
β-Catenin 92 kDa rabbit Cell Signaling 1:2,000 
Erk 42 kDa rabbit Cell Signaling 1:1,000 
p-ErkT202/T204 42 kDa rabbit Cell Signaling 1:1,000 
JNK 46, 54 kDa rabbit Cell Signaling 1:1,000 
p-JNKT183/Y185 46, 54 kDa rabbit Cell Signaling 1:1,000 
p38-MAPK 43 kDA rabbit Cell Signaling 1:1,000 
p-p38-MAPKT180/Y182 43 kDA rabbit Cell Signaling 1:500 
PKC-γ 78 kDa rabbit Abcam, Cambridge, MA 1:2,000 
p-PKC-γT514 78 kDa rabbit Abcam 1:1,000 
PKC-ζ 76 kDa rabbit Cell Signaling 1:1,000 
PKC-ζT410 76 kDa rabbit Cell Signaling 1:500 
Raf-1 65-75 kDa rabbit Cell Signaling 1:500 
Ras 21 kDa mouse Millipore, Billerica, MA 1:2,000 
Rb 110 kDa mouse Developmental Studies Hybridoma Bank, Iowa City, IA 1:100 
S6 34 kDa rabbit Cell Signaling 1:10,000 
p-S6S240/244 34 kDa rabbit Cell Signaling 1:5,000 
p-S6S235/236 34 kDA rabbit Cell Signaling 1:5,000 
Src 60 kDA rabbit Cell Signaling 1:2,000 
p-SrcY416 60 kDA rabbit Cell Signaling 1:500 
tubulin 50 kDa mouse Sigma Aldrich, St. Louis, MO 1:10,000 
Yap 75 kDa rabbit Cell Signaling 1:1,000 
p-YapS127 75 kDa rabbit Cell Signaling 1:1,000 
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Despite the significant similarity in their amino acid sequence, there is evidence that the three 
related Ras proteins examined here (H-Ras, K-Ras, N-Ras) function uniquely to alter cell growth and 
differentiation.  In this thesis, I have established that constitutively-activated forms of these Ras proteins 
differentially impact on the function of NSCs when expressed in a biologically-relevant context from their 
endogenous promoters.  First, I have demonstrated that only K-Ras, and not H-Ras or N-Ras, 
hyperactivation increases the proliferation of brainstem NSCs.  Second, I have demonstrated that K-Ras 
hyperactivation does not alter the cell fate decisions of NSCs upon in vitro differentiation.  Third, I 
determined that K-Ras*-mediated NSC hyperproliferation operates through a non-canonical downstream 
pathway that is dependent on the effector protein Raf and the cell cycle regulatory protein Rb.  Taken 
together, these observations define differential functions and mechanisms of action of the Ras molecules 
in one important CNS cell type. 
These findings complement and expand upon previous observations comparing the differential 
impact of Ras molecule activation in vivo and in vitro.  Our laboratory has previously demonstrated that 
loss of Nf1 gene expression in mature brain astrocytes leads to differential hyperactivation of the 
individual Ras molecules.  In these studies, following Nf1 gene inactivation in astrocytes, only the K-Ras 
molecule is hyperactivated [1].  Moreover, K-Ras hyperactivation in these cells increases astrocyte 
proliferation in vitro in a manner similar to loss of Nf1 protein (neurofibromin) expression.  In order to 
demonstrate that K-Ras hyperactivation can substitute for neurofibromin loss in the genesis of murine 
brain tumors (optic gliomas), Nf1+/- mice were generated in which K-Ras activation occurred in neuroglial 
progenitor cells.  Consistent with the in vitro studies, Nf1+/- mice with K-Ras hyperactivation developed 
optic gliomas in vivo.  In addition to this study in the brain, differential Ras molecule function has also 
been explored in a mouse model of colon cancer in vivo [2].  While expression of activated N-Ras in the 
colonic epithelium inhibits cell apoptosis, activated K-Ras increases epithelial hyperplasia.  Despite this 
increase in cell proliferation, K-Ras activation is not sufficient to initiate tumor formation in these mice on 
its own.  In colon cancers, genetic mutations leading to the loss of the APC tumor suppressor gene occur 
early in cancer progression, suggesting that loss of this protein functions in colon tumor initiation.  In the 
mouse, epithelial loss of the Apc protein in the colon causes adenocarcinoma formation.  To determine if 
Ras molecule activation alters the progression of these tumors, genetically engineered mice were used 
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that both lacked Apc expression and expressed activated forms of either K-Ras or N-Ras in the colonic 
epithelium.  In the context of Apc loss, K-Ras, but not N-Ras, activation led to high-grade dysplasia within 
the colonic epithelium.  This result indicates that K-Ras activation alone increases cell proliferation and, in 
a tumor environment, promotes colon cancer progression.  Taken together, these findings establish that 
the individual Ras molecules have different biological functions in vivo and that K-Ras is critical for 
regulating cell proliferation. 
In addition to the functional heterogeneity introduced by the distinct Ras molecules, other factors 
play important roles in determining how Ras functions in specific organs during life.  These critical 
variables include how the various Ras molecules operate in specific cell types, different regions within the 
same organ, and during the course of various diseases. 
 
CELL-TYPE SPECIFICITY OF RAS SIGNALING 
The ability of RAS to regulate the growth of discrete cell populations within the same organ may 
rely on the differential utilization of unique effector pathways operating downstream of RAS.  This cell 
type specificity can be generated by using different RAS molecules or changing the interaction of effector 
proteins with the same activated RAS molecule.  Of these potential RAS downstream signaling pathways, 
the canonical RAF/MEK/ERK effector pathway is the predominant signaling cascade important for growth 
regulation in leukemic cells, hematopoietic cells, osteoblasts, and some populations of neural progenitor 
cells [3-6].  Nevertheless, recent data, including those presented in this thesis, suggest that RAS 
signaling may occur through other effector pathways in a cell type-specific manner.  Here, I have 
elucidated one such pathway required for hyperactivated K-Ras-mediated increased NSC proliferation.  
Other cell types in the mammalian brain, including neurons and astrocytes, also rely on different non-
canonical RAS signaling mechanisms to regulate their behavior. 
Recent studies from our laboratory have identified and characterized non-conventional RAS 
effector pathways which regulate neuronal function. In the context of NF1, the Ras-GAP protein 
neurofibromin was originally thought to regulate glial and neuronal cell biology through Ras-dependent 
and Ras-independent signaling pathways, respectively [7].  Upon heterozygous Nf1 gene inactivation, 
there is a reduction in neuronal intracellular cyclic AMP (cAMP) levels, leading to decreased axon 
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lengths, growth cone areas, and survival in vitro.  The importance of cAMP to these neuronal phenotypes 
is underscored by the finding that pharmacological agents that inhibit cAMP degradation or increase 
cAMP production restore Nf1+/- axonal lengths, growth cone areas, and survival to wild-type levels.  The 
idea that cAMP production by neurofibromin operated in a Ras-independent manner derived from 
experiments in which pharmacological inhibition of Mek or PI3K/Akt signaling had no effect on these 
defective Nf1+/- phenotypes. However, recent work demonstrated that cAMP homeostasis is actually 
Ras-dependent.  In neurons, neurofibromin regulates cAMP through inhibition of atypical PKC (PKCζ), 
leading to Gαs and adenylyl cyclase activation [8].  Upon reduced expression of neurofibromin in Nf1+/- 
neurons, the activity of both Ras and PKCζ is increased.  This subsequently inhibits Gαs and adenylyl 
cyclase activity and causes depletion of cAMP.  Genetic and pharmacologic inhibition of Ras activity in 
Nf1+/- neurons restores cAMP levels and neuronal axon lengths to those of wild-type neurons.  These 
results demonstrate that neurofibromin regulates cAMP levels in a Ras-dependent manner.  This pathway 
is unique to brain neurons, as PKCζ is not expressed in brainstem NSCs (Supplemental Figure S3.1), 
precluding this pathway from regulating NSC growth and underscoring cell type-dependent signaling 
differences. 
Similar to NSCs and neurons, astrocyte growth is also regulated by Ras, but in a manner 
dissimilar to neurons and NSCs. As outlined above, K-Ras hyperactivation increases astrocyte 
proliferation and is sufficient to form optic gliomas in Nf1+/- mice [1].  In Nf1-deficient astrocytes, Ras 
hyperactivation leads to greater cell proliferation through hyperactivation of the mammalian target of 
rapamycin (mTOR) complex [9].  As such, the increased proliferation of Nf1-/- astrocytes is reduced to 
wild-type levels following treatment with the mTOR inhibitor rapamycin.  While the precise mechanisms 
responsible for mTOR activation in astrocytes remain to be completely elucidated, recent studies have 
demonstrated that neurofibromin regulation of brainstem astrocyte proliferation in vitro and optic glioma 
growth in vivo involves mTOR activation mediated by both the PI3K/AKT and RAF/MEK RAS effector 
pathways [10].  Moreover, unlike other cell types, neurofibromin mTOR activation does not depend on the 
tuberous sclerosis complex proteins tuberin and hamartin [11].  Tuberin can be phosphorylated by MEK 
or AKT, leading to hyperactivation of the RAS homolog enriched in brain (Rheb) molecule [12-15]; 
however, Rheb activation does not result in increased astrocyte growth in vitro or optic glioma formation 
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in Nf1+/- mice in vivo [11].  Similarly, genetic silencing of Rheb has no effect on Nf1-deficient astrocyte 
growth.  Taken together, these studies demonstrate that neurofibromin loss leads to K-Ras 
hyperactivation, which subsequently activates mTOR through either the Mek or Akt effector proteins to 
increase astrocyte proliferation.  
A potential mechanism for cell-type specificity of Ras function is suggested by another recent 
study from our laboratory.  Although Nf1-associated gliomas (pilocytic astrocytomas) are caused by 
inactivation of both Nf1 alleles, sporadic pilocytic astrocytomas are caused by mutations at the B-RAF 
gene locus.  In these mutations, the genetic sequence encoding the B-RAF kinase domain is fused to a 
portion of a gene of unknown function, KIAA1549.   Expression of this B-RAF:KIAA1549 fusion gene (f-
BRAF) leads to increased activation of the downstream effector proteins Mek and Erk in both cerebellar 
astrocytes and NSCs [16].  However, only f-BRAF-expressing NSCs, but not astrocytes, demonstrate 
increased proliferation relative to wild-type cells.  An analysis of downstream effector proteins revealed 
that mTOR activity is increased in f-BRAF-expressing NSCs, but not in astrocytes.  Additionally, the 
protein tuberin, which normally inhibits mTOR activity, is more highly phosphorylated (inactivated) in 
these NSCs compared to the astrocytes.  Mechanistically, this cell type-specific phosphorylation of 
tuberin results from the differential subcellular localization of this protein in NSCs and astrocytes.  In 
astrocytes, cell fractionation reveals that tuberin is localized to subcellular membranes whereas in NSCs, 
tuberin is found exclusively in the cytosolic fraction.  It is thought that the cytosolic localization of tuberin 
in NSCs may allow this protein to be phosphorylated by Erk, such that mTOR activity and cell proliferation 
is increased.  In contrast, tuberin in astrocytes is sequestered at the membranes, thereby precluding the 
tuberin-Erk interaction from occurring.  This study provides evidence that the subcellular localization of 
effector proteins can account for differential signaling in different cell types.  
Collectively, these observations demonstrate that activated RAS can differentially control the 
growth and function of individual cell types through a diverse number of cell type-specific downstream 
effector pathways.  Moreover, this third study suggests a mechanism by which RAS interacts with 
different effector proteins such that activation of the same protein activates different effector pathways in 
a cell type-specific manner. 
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REGIONAL HETEROGENEITY OF RAS SIGNALING   
In addition to cell type-specific responses to RAS signaling, NSCs isolated from different brain 
regions also respond uniquely following RAS activation.  In this regard, Nf1-/- NSCs isolated from the 
brainstem proliferate faster and undergo more gliogenesis in vitro and in vivo relative to Nf1-/- NSCs 
isolated from the brain cortex.  An analysis of downstream effector molecules responsible for transmitting 
the Ras growth-promoting signal in these two NSC populations reveals that NSC proliferation and 
differentiation is dependent on mTOR complex 2 (mTORC2)-mediated activation [17].  This mTOR 
complex is characterized by the presence of the Rictor protein, which allows mTOR to function as an 
activator of AKT through serine 473 phosphorylation. The differential capacity of brainstem NSCs to 
increase their proliferation and glial differentiation following neurofibromin loss and mTOR activation 
results from three-fold more expression of Rictor in these NSCs relative to those derived from the cortex. 
Silencing of Rictor expression reduced the hyperproliferation and gliogenesis observed in Nf1-/- 
brainstem NSCs, establishing differential expression of one downstream effector as a key determinant in 
dictating brain region-specific signaling and cellular function.  In support of these data, brain region 
heterogeneity is also observed upon expression of the f-BRAF protein in NSCs isolated from the 
cerebellum and cortex.  Similar to the results above, f-BRAF expression increases the proliferation of 
cerebellar NSCs, but not cortical NSCs [16]. 
In conjunction with the data presented in this thesis, recent work suggests that the individual RAS 
molecules may also signal in a region-specific manner.  When expressed in cortical progenitor cells in 
vitro, two separate hyperactivated H-Ras constructs (H-RasG12V, H-RasG12S) inhibit neurogenesis, induce 
neural progenitor cell proliferation, and promote glial cell differentiation [18].  Moreover, introduction of the 
same constructs via in vivo electroporation during the embryonic neurogenic period (E13/E14) induces 
cell proliferation and premature gliogenesis.  These data highlight an important role for H-Ras* function in 
specifying glial versus neuronal cell fates in the developing neocortex.  In this thesis, activation of H-Ras 
(H-RasG12V) at a similar time point (E9.5) in the brainstem did not cause changes in glial or neuronal cell 
formation.  Moreover, we have examined the impact of H-Ras activation in brainstem NSCs in vitro and 
found that this is insufficient to change NSC proliferation or alter NSC cell fate decisions relative to wild-
type NSCs.   
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Taken together, these studies suggest that the regional specificity of RAS signaling may be 
conferred by differential expression of RAS downstream effector proteins or through regionally-restricted 
roles of the individual RAS molecules themselves.  To the second point, we have not yet explored 
whether the individual RAS molecules function differently by brain region.  If this proves to be accurate, 
further work will be necessary to determine the mechanistic basis by which region-specific, molecule-
specific RAS signaling could occur in the brain. 
 
RAS SIGNALING IN DISEASES OF THE CENTRAL NERVOUS SYSTEM 
 Additional insights into differential RAS signaling function can be realized by studying the 
consequences of RAS hyperactivation in the context of various brain disorders.  In NF1, affected 
individuals can develop a wide variety of neurological problems that reflect abnormalities in neuronal 
(learning disabilities and seizures) and astrocytic (optic gliomas) biology.  This highlights a particular 
vulnerability of multipotent NSCs to changes in NF1 gene function, which could impact on the 
development and function of both differentiated cell types.  In agreement with previous studies from our 
laboratory, I have demonstrated that Nf1-/- NSCs proliferate faster and give rise to more astrocytes upon 
differentiation relative to wild-type NSCs in vitro (Figure 4.1).  Moreover, Nf1 gene inactivation in BLBP-
Cre-expressing NSCs in vivo leads to increased astrogliogenesis in the brainstem of PN18 mice relative 
to littermate controls (Figure 4.2).  While the behavior of these Nf1-deficient NSCs is similar to that of K-
Ras* NSCs described in this thesis, the mechanisms underlying their altered NSC function differs.  Here, I 
have demonstrated that K-Ras hyperactivation increases NSC proliferation in a Raf/Rb-dependent 
manner.  However, using NSCs from the same brain region and time of development, we have previously 
demonstrated that Nf1-deficient NSCs undergo increased proliferation in an mTOR/Rictor-dependent 
manner to activate the downstream effector protein Akt [17].  To determine if this pathway functions upon 
K-Ras activation, I examined the activity of both Akt (p-AktS473) and S6 kinase (p-S6240/244) in K-Ras* 
NSCs and found that neither protein was hyperactivated in K-Ras* NSCs relative to wild-type NSCs 
(Supplementary Figure S3.1A).  As a negative regulator of Ras, the loss of neurofibromin expression is 
known to increase RAS activity.  Therefore, it stands to reason that hyperactive Ras could impact NSC 
growth in a manner similar to Nf1 gene inactivation.  However, these results demonstrate that this is not 
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the case and instead indicate that neurofibromin and K-RAS regulate the growth of the same cell 
population differently.  
 RAS also functions differently in different types of cancers.  Of all cancers, RAS pathway 
dysregulation is an important step in cancer initiation as approximately 30% of all cancers arise from 
hyperactivating mutations in RAS [19].   Despite the widespread importance of RAS to tumorigenesis, the 
individual RAS molecules do not contribute equally to this process.  For example, K-RAS mutations are 
found in 22% of all cancers, whereas H-RAS mutations are observed in only 8% of malignancies [19].  N-
RAS mutations occur even more rarely, occurring in approximately 3% of all cancers.  Some of this 
discrepancy can be accounted for by the developmental origin of the tissues in which these cancers 
develop.  In tissues of endodermal origin (lung, pancreas, colon), cancers are most commonly associated 
with K-RAS mutations, while N-RAS mutations are often associated with cancers of the hematopoietic 
system [20-23].  It is interesting to note that progenitor cells in these tissue populations have been shown 
to be especially susceptible to activating RAS mutations, providing a cellular basis for tumor formation 
and suggesting a potential target for anti-cancer therapies [2, 21, 24].  These studies indicate that there is 
inherent heterogeneity in RAS pathway hyperactivation underlying the formation of different tumors. 
 Future studies could address this differential contribution of each hyperactivated RAS molecule to 
brain tumorigenesis using the endogenous RASLSL mice used in this thesis.  It is clear that K-Ras 
hyperactivation in terminally differentiated astrocytes is sufficient for tumor formation in the optic nerve, a 
result that merits further exploration on the tumorigenic consequence of K-Ras hyperactivation in NSCs 
[1].  Moreover, as K-Ras activation alone increases the growth of NSCs, we attempted to examine 
whether CNS tumors arise in aged K-RasBLBP mice.  Unfortunately, efforts to evaluate tumor susceptibility 
in these mice were not possible as aging beyond 18 days of age caused these mice to form an apparent 
rectal prolapse between 5-8 weeks of age (n=4), which required subsequent euthanasia. Follow-up 
necropsy results revealed squamous cell papilloma of the vagina and/or anus yet there were no 
indications of CNS-related tumors at this time point.  Although this result limits the utility of K-RASBLBP 
mice in evaluating the tumorigenic potential of hyperactivated K-RAS in NSCs, future studies might 
consider exploring this question using an alternative, NSC-specific Cre recombinase driver.  
 Taken together, these examples indicate that the context in which the RAS pathway is activated 
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varies in different diseases.  As an example, in cancers and in the NSCs examined in this thesis, RAS 
pathway hyperactivation is the result of oncogenic RAS mutations, which may result in different levels of 
RAS activity than occurs upon the loss of a RAS regulatory protein such as neurofibromin.  This has 
potential implications in how the RAS pathway might be targeted in different diseases.   
 
SUMMARY AND SIGNIFICANCE 
 The requirement for RAS signaling in normal cell growth complicates efforts to inhibit RAS 
pathway hyperactivation in a specific manner and without the potential for off-target effects.  This 
emphasizes a need for therapeutic options that more specifically target aberrant RAS activity in specific 
cell types, specific organ regions, and in specific diseases.  The H-RAS, K-RAS, and N-RAS molecules 
described in this thesis are ubiquitously expressed across different mammalian cell types.  However, here 
we have described mechanisms that confer specificity on RAS molecule signaling.  First, the individual 
RAS molecules can be activated differently in various cell and tissue types.  Second, the expression 
and/or localization of effector proteins differentially alters the interactions between RAS and its 
downstream signaling pathways.  Third, activation of the same RAS molecule in the same cell type can 
alter cell function differently depending on how RAS is activated, such as by an oncogenic mutation within 
RAS or by gain-of-function/loss-of-function mutations to other components of the RAS signaling pathway.  
These mechanisms provide a potential means by which to inform the development of targeted therapies 
that reduce RAS pathway hyperactivity in specific tissues, cells, and in the various RASopathies.  
It is possible that therapies could be developed that inhibit RAS pathway activity in a tissue-
specific manner.  While studies have implicated active K-Ras as the driver of cell proliferation in both the 
brain and colon, the Ras effector pathways operating in these tissues are not equivalent.  This provides 
an opportunity to inhibit K-Ras-mediated astrocyte proliferation in brain tumors by targeting the mTOR 
complex or, conversely, targeting colon hyperplasia by inhibiting Mek/Erk activity.  Elucidation of 
additional Ras tissue-specific pathways may afford additional opportunities to target RAS hyperactivation 
in individual tissues.  
 Within the same tissue, there is growing evidence that RAS can regulate the function of individual 
cell types through the use of cell type-specific effector pathways. In the brain, this represents a 
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remarkable opportunity to target RAS signaling in individual cell types rather than by globally inhibiting the 
RAS pathway.  Moreover, this development is especially promising for the treatment of disorders that are 
characterized by defective regulation of multiple cell types, such as in individuals with NF1.  In this 
disorder, one might envision that targeting of the RAS/PKCζ/Gαs pathway in neurons could effectively 
treat children presenting with learning and memory disabilities.  In theory, these treatments could restore 
cAMP levels to those found in normal neurons.  Alternatively, in children affected by Nf1-associated optic 
gliomas, therapies that target RAS/mTOR activity may prove valuable in inhibiting the proliferation of 
astrocytes that make up the bulk of these tumors.  Additionally, the differential localization and expression 
of effector proteins in different cell types suggests that drugs that modulate the behavior and localization 
of effector proteins could allow for specific targeting of RAS signaling.  Hypothetically, these cell type-
specific approaches may demonstrate increased efficacy over conventional treatments targeting overall 
RAS signaling (i.e. lovastatin for learning disabilities) although more work is required before they can 
translate to the clinic. 
Lastly, disease-specific mechanism by which the RAS pathway is activated in individual disorders 
may alter how therapeutic approaches reduce aberrant RAS pathway hyperactivation.  Despite identifying 
RAS as the critical operator underlying the neuro-cardio-facio-cutaneous disorders, the nuances of the 
individual disorders likely result from the occurrence of disorder-specific mutations in different 
components of the RAS pathway.  In NF1, NSCs are especially sensitive to NF1 gene inactivation in 
order to account for defects in the function of both neurons and astrocytes in patients with this disorder.   
Nevertheless, it is unknown how Nf1 loss in NSCs may result in the differential activation of the three Ras 
molecules relative to one another.  While the current thesis is an important first step in understanding how 
RAS alters NSC function on its own, valuable follow-up studies will apply this knowledge to activating the 
Ras molecules in a manner consistent with Nf1 gene inactivation. 
 The studies discussed here demonstrate that RAS signaling extends far beyond the 
RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways that are traditionally accepted as the primary 
RAS effector pathways.  Indeed, a great deal of complexity and specificity is conferred upon RAS 
signaling through the utilization of other, non-conventional effector pathways.  While this thesis has 
focused on the differential function of RAS signaling, there is undoubtedly similar utilization of non-
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conventional pathways downstream of other developmental pathways, such as WNT, Notch, TGF-β, and 
hedgehog signaling.  This cautions against the assumption that certain proteins signal via only a limited 
subset of effector pathways.  Clarification of the effector pathways that confer specificity on these 
developmental pathways will facilitate more targeted approaches to regulate aberrant pathway signaling. 
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Figure 4.1. Nf1 loss results in increased NSC proliferation and glial cell differentiation in vitro.    
Nf1-/- NSCs proliferate faster than WT controls as measured by (A) direct cell counting (p<0.001) and (B) 
the percentage of Ki67+ proliferating cells (arrowhead) in Nf1-/- neurospheres (p<0.01).  (C) Nf1-/- NSCs 
give rise to increase numbers of GFAP+ astrocytes and O4+ oligodendrocytes (p<0.001) but not Tuj1+ 
neurons. 
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Figure 4.2. Nf1 loss in NSCs leads to increased gliogenesis in vivo. (A) Nf1 loss in BLBP-Cre-
expressing NSCs (Nf1BLBPCKO) leads to a 3.7-fold increase in brainstem GFAP+ astrocytes (***p<0.001). 
(B) Nf1BLBPCKO mice do not exhibit altered numbers of APC+ oligodendrocytes. 
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